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The TCR coreceptors CD4 and CD8 are crucial for thymocyte 
development and effector function of T cells. L2a was identified as a cis-acting 
DNA element putatively involved in CD8 expression. The L2a element has the 
properties of a nuclear matrix attachment region (MAR). It interacts with two 
MAR-binding proteins, SATB1 and CDP/Cux, through separated AT-rich 
regions, L and S. L2a mutants with an increased inter-LS region have 
decreased CDP/Cux binding, suggesting that both sites are required for binding 
at the same time. Upon binding of SATB1, these L2a mutants display altered 
DNase I hypersensitivity (DH) in the inter-LS region. A palindromic DNA 12-mer 
proximal to the S site was found to alter interactions between L2a and its 
binding proteins, and two 12-mer binding proteins have been identified.  
Transgenic studies suggested that L2a is potential silencer for regulating 
CD8 expression. Transgenes driven by the L2a-containing DH cluster II and an 
enhancer E8I showed no reporter expression in thymic subsets or in peripheral 
splenocytes or in intraepitheal lymphocytes (IELs). Deletion of L2a resulted in 
 vi
robust reporter expression, even in the DP population. A small fraction (1~5%) 
of the L2a-containing transgenic CD8SP thymocytes and peripheral T cells 
“escaped” L2a-silencing, suggesting that compensatory mechanisms can 
overcome silencing during transition to the CD8SP stage. Crossing this 
transgene onto a SATB1 knockdown background decreased the escape rate, 
indicating that SATB1 is involved in re-starting silenced CD8 expression. 
Knock-in studies were carried out to further investigate the function of 
L2a. The M1 mutant knock-in mice, which have altered binding sites that 
abolish SATB1 interaction, showed no significant changes in CD8 expression. 
Knock-in mice in which the entire L2a element was deleted (ΔL2a) showed 
modestly increased CD8 levels in CD8SP thymocytes, peripheral CD8 T cells, 
and IELs. These effects are indicative of the consequences of losing a potential 
CD8 silencer, but their modest magnitudes suggest that other compensatory 
mechanisms suppress L2a function in the germline. Finally, targeted deletion of 
L2a resulted in significantly decreased CD8αα expression on splenic dendritic 
cells, implicating an unsuspected regulatory role for L2a in the lineage 
development of this myeloid sub-population. 
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1.1 T cell development and TCR coreceptors 
1.1.1 An overview of T cell development 
The development of thymocytes is a highly ordered and coordinated 
process. It provides a good model system for the study of regulatory 
mechanisms, and it has been used widely in the analysis of cell fate decisions 
and lineage commitment in vertebrates. Distinct developmental stages of 
thymocytes are defined by the expression of numerous regulatory components 
and cell surface molecules.  
T cells mediate immune responses through cell surface T-cell receptors 
(TCRs). TCRs are composed of four invariant chains and two variable chains 
which form the interface to bind antigens [1]. Most T cells express TCR α and β 
variable chains. These cells develop in the thymus and recognize peptide/MHC 
class I or II molecules [2]. The majority of TCRαβ positive T cells also express 
CD4 and CD8 coreceptor molecules on their surface. The major functions of 
the coreceptors are enhancing adhesion and facilitating signaling through the 
TCR. They bind to the invariable regions of MHC class I or II molecules and 
interact with membrane-associated signaling molecules to facilitate TCR signal 
transduction [3-6]. CD4 is typically expressed on T helper (Th) cells, and it 
interacts with MHC class II molecules. CD8 is expressed on cytotoxic T cells 
and has specific interaction with MHC class I molecules. Therefore the CD4 
and CD8 coreceptors are useful markers for T-cell sub-lineages and MHC 
restriction identification [7-11]. Both coreceptors are important for the 
recognition of antigen/MHC complexes by TCRs in both developing and mature 
T cells [12].  
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Developing thymocytes can be subdivided into four populations based 
on CD4 and CD8 coreceptor expression. At early stages, the thymocytes 
express neither CD4 nor CD8. These double-negative (DN, CD4–CD8–) 
thymocytes have functionally rearranged TCR-β chain genes. DN thymocytes 
transit to the double positive (DP, CD4+CD8+) stage during the rearrangement 
of the TCR-α chain gene and undergo an antigen-dependent selection process. 
Positive selection is accompanied by down-regulation of either CD4 or CD8, 
leading to single positive (SP, CD4+CD8– or CD4–CD8+) T cells that express 
functional TCRs. Mature thymus-derived TCRαβ positive T cells express either 
CD4 or CD8 molecules which interact with antigen-presenting MHC molecules 
that are engaged with the TCR activation complex. 
 
1.1.2 From DN to SP mature thymocytes  
The immature DN cells constitute approximately 1-5% of total 
thymocytes, and they can be subdivided into several stages based on the 
expression level of the surface molecules CD117, CD44, and CD25. In brief, 
the thymic lymphoid progenitor cell (CD117+CD44+CD25–) develops into the 
pro-T cell (CD117–CD44+CD25+), then to the pre-T cell (CD117–CD44–CD25+), 
and finally to the CD117–CD44–CD25– stage. A functional pre-TCR complex is 
formed at the pre-T cell stage due to the rearrangement and expression of the 
TCR-β chain gene. Signaling through this complex leads to the β-selection 
process and features proliferation and expansion of the thymocytes [13-16]. In 
addition to β-selection of DN thymocytes, pre-TCR complex signaling also 
leads to rearrangement of the TCRα gene and to the expression of CD4 and 












Fig.1. A simplified model of T cell development 
Upon entering the thymus, thymocyte precursors rearrange their TCR-β genes as well as 
their TCR-γ and TCR-δ genes. Expression of the rearranged TCR-β allele forms part of the 
pre-TCR complex, which also contains CD3 components and the pre-T-α invariant chain, 
on the surface of DN thymocytes. After the stimulation of pre-TCR signals, DN cells 
differentiate into DP thymocytes, and they rearrange the TCR-α gene. A TCR-αβ complex, 
which contains TCR-α, TCR-β chains and CD3 components, is expressed on the surface 
of DP cells. Thymocytes with low avidity for self-peptide/MHC complexes die by neglect in 
the thymic cortex, and those with high avidity are eliminated by negative selection (not 
shown). DP cells with intermediate avidity for self-peptide/MHC complexes survive and 
undergo positive selection to differentiate in to mature CD8SP (MHC class I restricted) or 




About 80-90% of thymocytes are DP cells, and they express a mature 
TCRαβ receptor complex on the surface. The DP thymoctes undergo positive 
and negative selection [9] [18], and only a small portion of them develop into 
CD4SP or CD8SP mature thymocytes. During this process, the avidity of the 
TCR for intrathymic self-MHC/peptide complex determines which of the DP 
thymocytes will be rescued from apoptosis. Most DP thymocytes die within a 
few days of generation by neglect because their TCRs fail to be engaged and 
cannot mediate signal transduction [19] [20]. If the thymocytes express TCRs of 
high avidity for self-MHC/peptide complexes, they will be eliminated by TCR-
induced apoptosis (negative selection). Therefore, only a few DP thymocytes 
that express a TCR complex capable of recognizing self-MHC/peptide 
complexes with appropriate avidity will be rescued from cell death and develop 
into CD4SP or CD8SP T cells [21-24] (Fig.1). 
 
1.1.3 Mechanisms of lineage decision  
The mechanism underlying CD4 and CD8 lineage commitment has been 
the subject of intense investigation over many years, and recent reports have 
begun to reveal the molecular details [25]. MHC specificity initially was linked to 
CD4/CD8 lineage determination by the instructive or the stochastic/selective, 
model [26, 27]. The instructive model proposed that the engagement of both 
the TCR and the coreceptor by MHC molecules directs CD4/CD8 lineage 
commitment [28, 29]. According to this theory, thymocytes are matched with 
their lineage and MHC specificity, which requires that signaling via MHC Class I 
specifically promotes positive selection and differentiation into CD8 T cells. 
Similarly, MHC class II signaling promotes CD4 T cell differentiation. In contrast, 
the selective model proposed that lineage choice is not dependent on 
TCR/MHC signals but is induced by other ligands. Thus, some of the 
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thymocytes are mismatched, but they are eliminated later because of lack of 









Fig.2. A schematic of the kinetic model of lineage decision  
DP thymocytes are preprogrammed to respond to TCR coreceptor signals regardless of 
the MHC specificity. They convert into CD4+CD8low intermediate cells by terminating CD8 
transcription. Continued signaling drives intermediate thymocytes to differentiate into 
CD4SP cells. Ceased signaling leads to “coreceptor reversal” and development into 






Recent suggestions indicating that lineage commitment may be 
determined by signal duration, not signal intensity, have lead to two related 
signal-duration models [25, 34, 35]. One model proposes that the duration of 
the TCR signal instructs the fate of DP thymocytes; ie, prolonged signals drive 
DP thymocytes to CD4SP cells, and short-duration signals instruct them to 
differentiate into CD8SP cells. This model suggests that lineage commitment 
occurs in DP thymocytes before any changes in transcription or translation of 
the coreceptors. Alternatively, the kinetic signaling model postulates that 
lineage decision is influenced by differential regulation of coreceptor gene 
expression. All DP thymocytes transit into a CD4+8low intermediate stage by 
transiently terminating CD8 transcription upon receiving intrathymic TCR co-
receptor signals. These intermediate cells will develop into CD4SP cells if the 
signals persist. Cessation of TCR signaling will reinitiate CD8 gene transcription 
and terminate CD4 transcription. Thus, these intermediate thymocytes will 
differentiate into CD8SP cells, a process originally termed “coreceptor reversal” 
[34] (Fig.2). 
Identification of the cis-acting regulatory elements and factors controlling 
CD4 and CD8 gene transcription has led to support of both models. Further 
studies on the transcriptional regulation of coreceptor genes are required to 
understand more about CD4/CD8 lineage differentiation. 
 
1.2 Regulation of CD4 and CD8 coreceptor expression 
1.2.1 CD8 genes and proteins 
The CD8a and CD8b genes reside 36 kb apart on mouse chromosome 6. 
The CD8b gene lies upstream of the CD8a gene and they are in the same 
transcriptional orientation [36]. These closely linked coreceptor genes have 
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partially overlapping but distinct expression patterns, which indicate they may 
be regulated both independently and coordinately.  
The CD8 cell surface glycoprotein can be expressed as two isoforms: 
CD8αβ heterodimers or CD8αα homodimers [37, 38]. Thymus-derived T cells 
usually express CD8αβ heterodimer on their surface, whereas extrathymically 
derived intraepithelial lymphocytes (IELs) from the gut [39, 40] and CD8+ 
dendritic cells (DCs) [41] express CD8αα homodimers.  
CD8αβ is a disulfide-bonded heterodimer of two proteins, CD8α and 
CD8β, which are encoded by the CD8a and CD8b genes, respectively. By 
virtue of its interaction with a monomorphic determinant on the class I MHC 
molecule, the CD8αβ molecule functions as a corecepter for recognition of a 
target peptide/class I MHC complex by the αβ-TCR of a class I-specific T 
lymphocyte. In addition to increasing the avidity of the interaction, CD8αβ 
interaction provides a signaling function to T lymphocytes through the p56lck 
tyrosine kinase associated with the cytoplasmic tail of the CD8α subunit. Mice 
with a CD8a gene disrupted by homologous recombination lack class I MHC-
specific cytotoxic T lymphocytes [42]. When the CD8b gene was disrupted [43] 
or its cytoplasmic tail was removed [44], mice expressed T cells with CD8αα 
homodimers, but they had abnormal negative and positive selection. Thus both 
CD8 subunits are important for the function of class I MHC-specific T cells and 
the development of thymocytes. 
 
1.2.2. DNase I hypersensitivity and chromatin structure 
In the eukaryotic nucleus DNA is associated with histones and is 
packaged into chromatin [45]. Chromatin is condensed into a 30 nm diameter 
fiber and is organized into nucleosomes, each of which consisting of 146 base 
pairs of DNA wrapped around a histone octamer core. The extent of chromatin 
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condensation is thought to be related to active and inactive states of gene 
transcription. A tightly condensed heterchromatin structure is most likely a 
silenced region of the genome, and this packaged structure is not accessible to 
transcription factors and enzymes. On the other hand, a decondensed 
euchromatin configuration is thought to be an active gene locus, and this 
chromatin structure is devoid of ordered nucleosomal arrays [46]. The 
transitional processes between closed and open chromatin configuration is 
termed chromatin remodeling. A number of studies have suggested that post-
translational modifications play an important role in controlling the closed or 
open chromatin state. Such modifications include glycosylation, 
phosphorylation, methylation, acetylation, and ubiquitylation [47-49]. Histone-
modification enzymes, such as histone acetyltransferases (HATs) and class I 
histone deacetylases (HDACs, play major roles in the chromatin remodeling 
process [50].  
The chromatin structures associated with differential DNA accessibility 
are the basis of the DNase I hypersensitivity (DH) assay. This method is widely 
used to identify DH sites in an expressing gene locus in its natural chromatin 
configuration. The DH sites likely indicate the location of cis-acting elements, 
such as enhancers and promoters, in the vicinity of genes [51]. DNase I 
hypersensitivity assays have been used to identify some of the major CD8 cis-
acting regulatory elements. 
 
1.2.3 cis-acting elements in CD8 gene regulation 
 Both DH site and transgenic reporter assays have been used to identify 
some of the major CD8 cis-acting regulatory elements. A long-range DH site 
assay revealed four (I-IV) DH site clusters in an 80 kb genomic fragment 
spanning the CD8a and CD8b genes in mouse [52] and six clusters covering 95 
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kb  in human [53]. Using transgenes derived from P1 bacteriophage clones 
containing large genomic inserts (approximately 80 kb of DNA covering CD8a 
and CD8b), several individual cis-acting regulatory elements were further 
dissected functionally. Four enhancers (E8I to E8IV) were demonstrated to be 
required for CD8 gene expression in CD8αβ T cells. They are located between 
the CD8a and CD8b loci and overlap with the DNase I hypersensitivity sites 
[54-60] (Fig.3). All four enhancers are CD8-lineage specific and are active at 







Fig.3. Map of the mouse CD8a and CD8b gene loci 
A map of the mouse CD8 gene locus showing four DNaseI-hypersensitivity (DH) clusters I 
to IV (CI-CIV). Triangles show DH individual sites. The horizontal bars denote the 
enhancers E8I, E8II, E8III, and E8IV. CIII-1,2 for E8I, CIV-4,5 for E8II, CIV-3 for E8III, and 
CIV-1,2 for E8IV. All BamHI (B) and relevant EcoRI sites are shown. Adapted from Kioussis 




Ellmerier et al. [55] and Hostert et al. [54] described an enhancer 
covering DH sites 1 and 2 (HS-1 and HS-2) within DH cluster III (Fig.3), which 
resides approximately 16 kb upstream of the transcription initiation site of CD8a. 
This enhancer, termed E8I, regulates expression of the CD8a gene in mature 
CD8 T cells and in intraepithelial lymphocytes (IELs) of the intestinal wall. More 
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interestingly, the E8I enhancer is inactive in double positive (DP) thymocytes 
but becomes functional only after positive selection. In 1998, two groups, 
Ellmeier et al [57]and Hostert et al [56], studied, in more detail, the roles of 
sequences within these DH sites using a reporter transgene encoding the 
human CD2 surface antigen. In agreement with the earlier studies, they 
observed that the E8I enhancer directed expression of the hCD2 reporter in 
CD8SP thymocytes, CD8 peripheral T cells and CD8αα IELs of both TCRαβ 
and TCRγδ lineages, but not in double positive thymocytes.  
Transgenic studies using genomic fragments derived from the cluster IV 
of DH sites revealed three other distinct enhancers (Fig.3). Enhancer E8II (CIV-
4,5) (located in a 4.3 kb BamHI fragment) directed reporter expression in DP 
and CD8SP thymocytes as well as in mature CD8 T cells. The E8III enhancer 
(CIV-3) (a 4.1 kb BamHI fragment) is only active in DP thymocytes. The 
enhancer E8IV (CIV-1,2) (a 3 kb EcoRI fragment) directed expression of 
reporter gene in CD8 T cells and a subset of CD4 T cells [57]. All three of these 
enhancers are active only in thymus-derived T cells, but not in CD8αα IELs. 
Some of the results described above suggested redundancy among 
these regulatory elements. Mice with targeted deletion of E8I (CIII-1,2) showed 
no effects on expression of CD8a and CD8b genes in thymus-derived T cells, 
but CD8 expression in IELs was eliminated [57]. This suggested that other cis-
acting elements could compensate for the loss of E8I in thymus-derived T cells. 
Targeted deletion of either E8I or E8II had no effect on CD8 expression in 
thymocytes or CD8 T cells [56, 57]. However, the combined deletion of both 
enhancers resulted in variegated expression of CD8 in DP thymocytes and 
reduced CD8 expression in mature CD8 T cells [58]. An indistinguishable 
population of CD8-negative thymocytes was identified by surface markers and 
functional phenotypes from the whole DP thymocyte population. 
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Further studies demonstrated that deletion of both E8I and E8II 
enhancers lead to altered chromatin remodeling during T cell development [61]. 
Using chromatin immunoprecipitation and DNA methylation assays, the CD8-
negative DP thymocyte population found in these mice was shown to have 
epigenetic modifications in the CD8a-CD8b locus, indicating an “off” state of 
chromatin. Crossing these mice to mice with conditional deficiency in DNA 
methyltransferase 1 (Dnmt1) [62] can partially revert the variegated CD8 
expression, suggesting a partial epigenetic block of CD8 expression due to 
deleted cis-acting elements. In addition, a zinc finger transcription factor MAZR 
(Myc-associated zinc finger-related factor [63]) was found to interact with 
enhancer E8II and negatively regulate chromatin modification at CD8 loci [61]. 
MAZR is highly expressed in DN thymocytes and is downregulated in DP and 
CD8SP thymocytes. MAZR can interact with the nuclear receptor corepressor 
N-CoR complex in DN thymocytes, and constitutive retroviral expression of 
MAZR led to variegated CD8 expression in DP thymocytes.  
Enhancer E8III is an active cis-acting element only in DP thymocytes. 
Recently, a core 285-bp fragment was identified as sufficient for directing CD8 
expression in DP thymocytes [64]. Further studies revealed that five elements 
within this fragment may contribute to full enhancer function [64]. Combined 
targeted deletion of the enhancer E8II and E8III in the mouse germline did not 
significantly change the expression levels of CD8α and CD8β in thymocytes or 
T cells [64]. Double-deficient mice had a small increase in CD4SP thymocytes, 
but CD3highCD5high cells in this population decreased by about 10%. This 
suggested that double deletion of E8II and E8III leads to mildly variegated 
expression of CD8 genes.  
Another recent study indicated that the E8III enhancer may play a role in 
determining CD4/CD8 lineage choice during the positive selection process [65]. 
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Transgenic mice expressing CD4 cDNA under the control of the CD8α 
promoter and E8III enhancer were bred to mice lacking endogenous CD4 
expression. Thus, all CD4 expression in these mice was controlled by the E8III 
enhancer. The authors found that the E8III enhancer was inactivated by TCR-
mediated positive selection signals. This might partially explain the early 
termination of CD8 gene expression in positive selected DP thymocytes 
(coreceptor reversal). Furthermore, the majority of MHC class II selected 
thymocytes developed into CD8 T cells with cytotoxic function in these 
transgenic mice. This might be a useful clue to understand the mechanism of 
CD4/CD8 lineage commitment.  
DH cluster II was inactive in all transgenic reporter analyses, but deletion 
of CII-1,2 resulted in altered CD8 expression in both DP thymocytes and CD8 T 
cells [59]. These results are similar to those observed in E8I-E8II double 
deletion mice. Variegated CD8 expression in DP thymocytes was found in CII 
knockout mice, as characterized by a reduction in the CD8 expression level on 
a fraction of DP thymocytes compared to the remaining DP cells. 
In summary, there are multiple lineage-specific and stage-specific cis-
acting elements involved in the regulation of CD8 expression, suggesting a 
complex regulatory network of these closely linked elements. Studies on the 
trans-acting regulatory factors interacting with them will be helpful in 
understanding the detailed mechanisms of CD8-lineage commitment.  
 
1.2.4 Proteins regulating CD8 expression 
Some nuclear protein factors play important roles in initiating and 
maintaining chromatin structure. They are expressed in various tissues and 
regulate expression of various genes, and generally they form large DNA-
protein complexes which can bend the DNA backbone and alter chromatin 
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structure. HMG (High-Mobility Group) box-containing proteins have been 
reported to be involved in T cell development [66, 67]. This protein family 
promotes interactions between proteins that bind to sites that are far apart on 
the linear DNA sequences. HMG-mediated interaction brings the DNA-bound 
proteins closer together and stabilizes their DNA-protein complex [68, 69]. Two 
HMG proteins, lymphoid enhancer-binding factor 1 (LEF1) and transcription 
factor (TCF1), have been shown to bind to sequences of many lymphoid-
specific genes. Deletion of LEF1 and TCF1 resulted in a block in thymopoiesis 
at the immature CD8SP stage [66, 67].  
Another HMG protein TOX (thymus HMG-box protein) was suggested to 
affect lineage commitment of T cell development. Over-expression of TOX 
leads to an increased CD8SP thymocyte subpopulation and a reduced CD4SP 
thymocyte subpopulation, possibly as a result of direct or indirect effects on the 
CD4 and CD8 gene loci [70]. More direct evidence came from studies on the 
proteins of the BAF (BRG- or hBRM-associated factor) chromatin complex. The 
BAF complex contains the HMG-box protein BAF57, and the BRG1 ATPase. 
This complex has chromatin-remodeling activities similar to those of the 
SWI/SNF complex. Mutation in the HMG DNA-binding domain of BAF57 
combined with mutated BRG1 leads to reciprocal regulation of CD4 and CD8 
genes; ie, CD8a and CD8b are activated and CD4 silencing is compromised 
[71]. 
Epigenetic regulation of T cell development has been demonstrated by 
studies of the protein factors involved in chromatin remodeling. Some DNA-
binding regulatory factors bind to specific sequence in genes and recruit other 
factors to form chromatin remodeling machineries in the same region. This 
results in long-range and long-term changes in the chromatin, whose heritable 
structure can determine the expression levels of a target gene [72]. The nuclear 
 13
protein Ikaros has been shown to be a transcription factor involved in 
epigenetic regulation. Ikaros can interact with both histone deacetylases and 
the SWI/SNF complex to act as a repressor or an activator [73]. It was found 
that Ikaros interacts with the regulatory elements located in the CD8a and 
CD8b loci in CD8αβ cells [74], and deletion of the DH cluster II (CII-1,2), one of 
the Ikaros binding regions, resulted in variegated expression of CD8 gene 
during DN to DP transition [59]. Furthermore, deletion of Ikaros or related family 
members led to impaired CD8α and CD8β expression [74, 75], and even 
resulted in impaired generation of B cells from multipotent haematopoietic 
progenitors [76].     
 
1.2.5 Regulation of CD4 gene expression 
The mechanisms of CD4 lineage differentiation are distinct from those of 
CD8 [11, 60]. Several T cell-specific enhancers have been identified within or 
close to the CD4 locus, but none of them are CD4-lineage specific [77]. Instead 
of enhancers, a CD4 silencer, which is contained within a 434 bp fragment 
located in the first intron of CD4 gene, can repress CD4 expression in CD8 T 
cells and DN thymocytes [78, 79]. Deletion of the CD4 silencer resulted in 
variegated CD4 expression, characterized by CD4 expression in a random 
fraction of CD8 T cells and CD4 silencing in the remaining CD8 T cells [80]. A 
conditional knockout of this silencer demonstrated that it is not required for 
maintaining the silencing of CD4 expression in mature CD8 positive cells [81]. 
However this fragment is crucial in the establishment of CD4 silencing during 
CD8 thymocyte development, which remains silencer-dependent until the end 
of positive selection. 
Additional functional studies of the CD4 silencer have identified several 
silencer-binding proteins, including RUNX (Runt-related transcription factor) 
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transcriptional regulators [82], SAF (silencer associated factor) [83], and the 
HES1 transcriptional repressor [84]. RUNX proteins have been characterized 
as CD4 silencing factors in CD8 lineage development. The RUNX family 
(RUNX1-3) of proteins contains a Runt DNA-binding domain, and all of them 
are expressed in the thymus. Results from knockout and conditional gene 
disruption experiments suggested that RUNX1 is actively represses CD4 
transcription in DN thymocytes, and RUNX3 is mainly involved in CD4 silencing 
in CD8 lineage development [82, 85]. SAF has been shown to bind to the 
central region of the CD4 silencer, but mutants of SAF binding sites have no 
effect on CD4 silencing [80, 83]. The HES1 transcription factor is a target of 
Notch proteins [86], and it binds to the CD4 silencer to promote silencer activity 
in vitro [84]. The function of HES1 remains unclear as further studies conflicted 
as to its role in CD4 silencing and CD8-lineage development [80, 87]. 
 
1.2.6. CD8αα homodimer 
The CD8αβ heterodimer is commonly expressed on thymocytes and 
CD8 conventional T cells which are MHC class I-restricted. In contrast, the 
expression of the CD8αα homodimer is not correspondent to MHC class I 
restriction of TCR [88, 89] and has been identified on various cell types, 
including IELs and dendritic cells (DCs) [90]. Previous cell culture transfection 
studies suggested that CD8αα can function as a TCR coreceptor [91]. However, 
it was later reported that CD8αα does not support the positive selection of 
conventional MHC class I-restricted T cells as effectively as CD8αβ in vivo [43, 
92-94]. 
In the lumen of the intestine, there is a large population of various T 
lymphocyte subsets. These intraepithelial lymphocytes reside as single cells 
scattered among the epithelial cells with a number ratio of 1:4-9, making them 
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one of the largest T cell population in the body [95]. The majority of IELs 
express CD8αα on their surface. CD8αα has not been reported to be T cell 
lineage-specific or TCR-specific. It is expressed on TCRγδ IELs, and it can be 
co-expressed with CD8αβ or CD4 coreceptors on TCRαβ IELs.  
There are two major subsets of IELs residing in the intestine. The first 
subset is the conventional IELs that express TCRαβ (MHC class I or II-
restricted) with a TCR coreceptor, CD4 or CD8αβ. Some of these IELs can 
induce CD8αα expression during their translocation to the intestine, but they 
still maintain expression of CD4 or CD8αβ, making them triple positive [96, 97]. 
The second IEL subset expresses TCRαβ or TCRγδ mostly with CD8αα, but 
without the conventional coreceptors, CD4 or CD8αβ. These CD8αα IELs use 
the FcεRIγ chain of the CD16 complex of natural killer (NK) cells as part of the 
TCR-CD3 complex, and they can express various NK receptors [98]. 
Furthermore, the TCR-mediated selection and activation of CD8αα TCRαβ IELs 
differ from those in conventional TCRαβ IELs [88]. 
Recently the function of CD8αα on IELs has been partially revealed. 
Mucosal T cells can be induced to express CD8αα upon translocation to the 
intestine, which indicates that the induction of CD8αα may be an adaptation for 
the function and survival of T cell in the intestine [96, 99]. CD8αα has a specific 
and strong interaction with the thymic leukemia (TL) antigen, a non-classical 
MHC class I molecule constitutively expressed by the epithelial cells of the 
small intestine [96, 100]. The interaction between CD8αα and TL ligand leads 
to the activation of IELs, which is characterized by reduced proliferation and 
cytotoxicity, but increased cytokine production [96]. These antigen-stimulated 
responses are significantly different from those of activated peripheral CD8 T 
cells, which are characterized by clonal expansion and cytolytic activity. 
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The expression of CD8αα is not unique for IELs. It was reported that 
CD8αα can be co-expressed with CD8αβ on activated conventional T cells and 
some T cell leukemias [37, 38], although it is not expressed on resting 
peripheral T cells. Using cytotoxic T lymphocyte (CTL) cell lines activated via 
their TCRs in vitro, it was found that the expression of CD8αα is up-regulated, 
whereas CD8αβ is down-regulated and internalized [101].  
More recently, CD8αα was reported to be transiently induced on a 
subset of conventional mature TCRαβ T cells after TCR activation [102]. This 
subset of CD8αα+ primary effecter cells expresses high levels of IL-7 receptors, 
which are commonly expressed on memory T cells and their predecessors. 
They can survive for a long time in vivo and differentiate into mature memory T 
cells [102].  CD8αα can not be induced in CD8α enhancer E8I knockout mice 
[58] during a primary response in vivo to lymphocytic choriomeningitis virus 
(LCMV). The knockout mice failed to generate CD8αβ memory T cells as well 
as secondary antigenic responses [102].  
CD8αα can also be induced in adoptively transferred CD4 T cells during 
their migration to the intestine of the recipient mice [97]. Whlie in vitro 
stimulated human CD4 T cells can express CD8αα [103, 104], the role of 
CD8αα in CD4 T cell memory has not been demonstrated. Regardless of their 
MHC restriction and TCR specificity, the expression of CD8αα is dependent 
upon TCR activation, suggesting that CD8αα functions as a TCR modulator to 
regulate T cell survival and differentiation.  
 
1.3 L2a as a cis-acting element that regulates CD8a gene expression 
1.3.1 Identification of the L2a element 
Carbone et al. reported that fusion of CD8 class I-restricted CTLs with 
the BW5147 thymic lymphoma resulted in CD8– hybridomas [105]. In these 
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hybridomas, the CD8a alleles of the CTL fusion partner were CpG methylated, 
a state characteristic of CD8– cells. Previous studies in our lab showed that in 
such hybridomas, CD8 expression is shut-off at the level of CD8a gene 
transcription [106], whereas CD8b gene expression is not affected [107, 108]. 
Stable transfection of BW5147 cells with a CD8a gene reporter carrying 
differing lengths of 5’ flanking sequences identified a putative regulatory 
element ~4.5 kb upstream as the target of negative regulation [106]. This DNA 
region is located within DH cluster II as defined by Hostert et al. [52].  
Further studies revealed that a 220 bp region of this regulatory element, 
named L2a, has the properties of a nuclear matrix attachment region (MAR). 
Two MAR-binding proteins, SATB1 and CDP/Cux, bind to L2a through two AT-
rich regions (called L and S) separated by a DNase I-hypersensitive region 
(referred to as the INTER-LS region) [106, 109] (Fig.4). DNase I footprinting 
indicated that SATB1 binds primarily to the L region and that CDP/Cux interacts 
with both L and S regions. A 12 bp palindromic sequence is located at the end 
of the INTER-LS region proximal to the S region. Further footprinting indicated 
that the binding of SATB1 to the L region results in a significant conformational 
change in the INTER-LS region. Binding of CDP/Cux with both L and S regions 























Fig.4. Schematic of the L2a element 
The L2a element is located approximately 4.5 kb upstream of the mouse CD8a gene 
(upper map). The 270 bp AccI/SstI fragment is expanded to show the L, S, and INTER-LS 
regions identified in footprinting studies. The palindromic 12-mer is also shown. Adapted 
from Banan et al. [109]. 
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1.3.2 Displacement switch model 
Based on previous studies, a displacement switch model was proposed 
[109] to explain the interaction of SATB1 and CDP/Cux proteins with the L2a 
element (Fig.5). In the absence of SATB1, CDP/Cux binds primarily to the S 
region, and it also interacts with the L site via one or more of its multiple cut 
domains. The interaction of CDP/Cux to L and S sites may result in some 
distortion of the INTER-LS region closest to the S region. In the presence of 
SATB1, any CDP/Cux bound to the L region is displaced by binding of SATB1. 
The L region is the primary binding site of SATB1, and the binding of SATB1 to 
the L site creates a structural distortion in the INTER-LS region, particularly in 
the palindromic 12-mer sequence adjacent to the S site. Both the competition 
for the common binding site with L and the introduction of structural distortion 
has been demonstrated [109]. The binding of SATB1 and the DNA distortion 
might alter the affinity of L2a for the nuclear matrix, and thereby affect the 
transcriptional regulation of the adjacent CD8α gene. Interestingly, binding of 
SATB1 to the L2a element can specifically induce DNase I hypersensitivity in 
the palindromic 12-mer sequence. Because palindromes are frequently sites for 
protein interaction, it is possible that an unidentified protein can interact with the 
12-mer and plays a role (together with CDP/Cux and SATB1) in the regulation 


















Fig. 5. Displacement switch model 
A displacement switch model has been proposed to describe the interaction of SATB1 and 
CDP/Cux with the L2a element. CDP/Cux interacts with the S regions primarily and 
contacts the L region. Interaction of SATB1 with the L region leads to the displacement of 
CDP/Cux. SATB1 induces conformational changes in the INTER-LS region, which may 
affect the association of the L2a element with the nuclear matrix and favor CD8a gene 





1.4 MAR regions and MAR-binding proteins 
1.4.1 Nuclear matrix 
In the eukaryotic cell nucleus, DNA is organized on at least two levels:  
into nucleosomes with histones and a 30 nm chromatin fiber, and by non-
histone proteins which define and maintain looped domains 10 to 100 kb in 
length [110]. Extraction of nuclei with high salt solutions [111] or the chaotropic 
agent, lithium diiodosalicylate (LIS) [112], leaves behind a structure called the 
nuclear matrix or scaffold (also called nuclear cage, nuclear ghost, and nuclear 
core [113]). The nuclear matrix retains the same size and shape as the nucleus 
and consists of a proteinaceous network, whose contents differ depending on 
the preparation methods. Nuclear matrices typically consist of a nuclear lamina 
with residual nuclear pore complexes, residual nucleoli, and a filament network 
connecting the lamina with residual nucleoli [114].  
Lamins have been known as the major components of the lamina in the 
nuclear matrix [115]. Further studies revealed that there are more than 200 
different proteins included in the nuclear matrix, such as DNA topoisomerase II 
and nuclear mitotic apparatus protein (NuMA) [116, 117]. Additional nuclear 
matrix proteins have been identified by mass spectrometry [118]. The 
composition of the nuclear matrix differs among normal cell types and among 
normal and malignant cells. The latter difference has been useful in identifying 
cancer cell markers [119-121]. 
 
1.4.2 Nuclear matrix-associated DNA regions (MARs) 
Nuclear matrices prepared by the LIS method contain matrix-associated 
DNA regions (MARs) which lie close to a number of different genes. MARs are 
thought to be the sites for the attachment of chromatin fibers to the nuclear 
matrix to form the 30 to 100 kb loop structures [122-125]. Generally MARs are 
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200-800 bp ATC-rich DNA regions and contain consensus sequences similar to 
topoisomerase II sites in Drosophila [126, 127]. MARs flank the kappa IgL and 
IgH enhancers [128, 129] and are located within transcription enhancers in 
three developmentally-regulated Drosophila genes [130]. MARs have been 
shown to be the in vitro binding sites for histone H1 and may affect histone H1-
dependent chromatin repression [131, 132].  
 
1.4.3 Regulatory function of MARs 
MARs are defined by their capacity to mediate nuclear matrix 
association and can be grouped into two distinct classes [133]. One class of 
MARs may contribute to control of gene expression by forming structures or 
topological boundaries between distinct domains of eukaryotic chromosomes. 
Examples of chromosome domain boundary elements are the A elements 
flanking the chicken lysozyme gene [134], the specialized structures which 
flank the Drosophila heat shock locus and the insulator elements at the 5’ end 
of the chicken β-globin locus [123, 135, 136].  
The second class of MARs may function as intragenic control elements. 
One example are the MARs located within the immunoglobulin heavy and 
kappa light chain loci [128, 129]. These MARs are adjacent to intragenic 
enhancers or between the promoter and the enhancer. They generally do not 
contribute to transcriptional control in either transient or stable transfection 
assays in B lymphoid cell lines [137-140]. However, the MARs flanking the IgH 
enhancer function in transcription of the rearranged µ chain gene in B cells of 
transgenic mice. Furthermore, MARs were shown to enhance the acetylation of 
histones at the IgH enhancer distal nucleosomes [141]. The MARs appear to be 
required for broader reorganization of chromatin and to contribute to long range 
chromatin accessibility. 
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MARs have been shown to be important transcriptional regulators of 
chromatin remodeling [142], which is likely because most of the HDAC and 
HAT activities are associated with the nuclear matrix [143]. Moreover, MAR-
binding proteins are involved in transcriptional regulation. For example, B cell 
regulator of IgH transcription (Bright) plays an important role in regulation of the 
IgH enhancer [144], and SATB1 can influence expression of a reporter gene 
flanked by MAR regions [145].    
 
1.4.4 Special AT-rich Binding protein 1 (SATB1) 
SATB1 was identified as a MAR-binding protein by Dickison et al. [146] 
from a thymic cDNA expression library screened with a concatamer containing 
the nucleation site for unwinding of the 3’ MAR flanking the IgH enhancer. They 
reported that SATB1 is expressed abundantly in thymus and modestly in brain 
and testis. Other studies have identified SATB1 expression in other tissues 
[147] and in T lymphocyte cell lines [106, 109]. SATB1 specifically binds to the 
minor groove of A/T-rich regions of DNA in which one strand is also rich in C 
(ATC regions), and it is a component of the nuclear matrix [146]. Some of the 
AT-rich regions in MARs have a strong tendency to unwind by extensive base 
unpairing [148]. SATB1 binding is very specific, and it does not bind to AT-rich 
regions without unwinding ability, even if the region has a very similar sequence.  













Fig. 6. Schematic diagram of mouse SATB1 
Dimerization domain, MAR-binding domain, and homeodomain are indicated. Two Cut-like 
repeats, CR1 and CR2, are highlighted in red boxes. The numbers correspond to amino 
acid positions. Adapted from [149, 150]. 
 
 
To isolate genomic SATB1-binding sequence in vivo, cross-linked and 
Sau3AI-digested chromatin from Jurkat T cell lysates were immunoprecipitated 
with SATB1-specific antibody [151]. SATB1 bound DNA was cloned and 
sequenced, identifying 16 SATB1-binding sequences. Subsequent in situ 
hybridization experiments indicated that SATB1 binds to the bases of the 
chromatin loops. Further studies suggested that the chromatin anchoring to the 
nuclear matrix and loop formation by SATB1 are cell-type dependent [151, 152]. 
Thus, SATB1 may regulate tissue-specific gene expression by organizing 
higher order chromatin structure. 
The murine SATB1 protein contains 765 amino acids and is 98% smilar 
to human SATB1 [153]. SATB1 contains a dimerization domain at the N-
terminus, a MAR-binding domain in the middle, two cut-like repeats, and an 
atypical homeodomain at the C-terminus [149] (Fig.6). SATB1 was previously 
reported to bind DNA as a monomer, but subsequent studies suggested it 
functions as a homodimer. The dimerization domain is important for SATB1 to 
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bind to DNA. Truncated SATB1 protein without this domain has no DNA binding 
activity and is not functional, even thought it retained an intact homeodomain 
and MAR-binding domain [150]. The homeodomain does not bind DNA, but it 
cooperates with the MAR-binding domain associated with the core-unwinding 
element in the base-unpairing region [149]. 
A number of SATB1-interacting proteins have been identified. Using 
yeast two-hybrid screening of a Jurkat T cell cDNA library, SATB1 was found to 
interact via its dimerization domain with a novel variant of RNA polymerase II 
subunit 11 (RPB11) [154]. In pre-T lymphocytes, SATB1 was reported to 
colocalize with the X-linked lymphocyte regulated (Xrl) protein, which is also 
expressed in late stage B-lymphoid cell lines [155]. Another MAR-binding 
protein CDP/Cux was shown to bind SATB1, and both of them are repressors 
of the MMTV promoter. The interaction between SATB1 and CDP/Cux 
abolished DNA binding ability of both proteins, relieving the transcriptional 
repression at the promoter [156]. However, unpublished data from our lab was 
unable to confirm an interaction between SATB1 and CDP/Cux (Ingrid Rojas, 
personal communication). 
Results from Kohwi-Shigematsu et al. [145] suggest that SATB1 may act 
as a negative regulator of gene expression. They stably transfected the BHK 
cell line, which expresses low levels of SATB1, with reporter genes containing 
or lacking flanking MARs. It appeared that SATB1 inhibited expression of the 
reporter containing the flanking MARs. SATB1 knockout mice are small in size, 
have disproportionately small thymi and spleens, and die at 3 weeks of age 
[157]. These mice exhibit neurological defects, such as an incomplete eye 
opening and clasping reflex. T-cell development was blocked mainly at the DP 
stage. The few peripheral CD4SP cells underwent apoptosis and failed to 
proliferate in response to activating stimuli [157]. Nearly 600 genes were 
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surveyed in SATB1-knockout thymocytes, and about 2% of them showed 
differences in expression [157]. RT-PCR results suggested that nine genes, 
including c-myc, had increased expression, which is consistent with the 
transcriptional repression shown by SATB1 previously.  
Since deletion of SATB1 is lethal and has multiple effects on T cell 
development, Nie et al [158] constructed SATB1-reduced transgenic mice that 
are homozygous for a T cell-specific SATB1-antisense gene and heterozygous 
for a SATB1-null allele. These transgenic mice are significantly smaller than 
wild type mice, but they are generally healthy. In these mice, the thymic SATB1 
protein level is significantly reduced, and there is a 3-fold reduction in CD8SP T 
cells in thymus, spleen, and lymph nodes. The composition of the thymus is 
similar to that of wild type with the exception of a slight increase in surface CD3 
expression on CD8SP thymocytes.  These results suggest an essential role for 
SATB1 late in the development and maturation of CD8SP T cells, possibly at 
the stage of coreceptor reversal [158]. 
Recent studies suggest that SATB1 interacts with proteins involved in 
chromatin remodeling. Using affinity purification, SATB1 was co-purified with 
the NURD (nucleosome remodeling and histone deacetylase) complex, which 
contains the ATP-dependent remodeling enzyme Mi-2, as well as HDAC1 and 
2, mSin3A, and MTA-2 [159]. The NURD complex has been implicated in 
transcriptional repression of several genes. SATB1 can recruit ATP-dependent 
chromatin remodeling complexes that modify histone acetylation and 
nucleosome placement over long distances (~7kb) in the IL-2Ra gene [159]. 
Furthermore, SATB1 can form a three-dimensional network structure in mouse 
thymocyte nuclei. It was suggested that tethering of genes to the SATB1 
network and orchestrated histone acetylation and methylation lead to gene 
activation or repression, depending on the locus [160]. 
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1.4.5 CCAAT Displacement Protein (CDP) 
The MARs flanking the IgH enhancer have been reported to have a 
negative regulatory function in T cells [161-163]. Sheuermann and Chen [162] 
identified a protein complex named NF-µNR, which binds to the MARs flanking 
the IgH enhancer. NF-µNR is present in T cells, macrophages, fibroblasts and 
early (but not mature) B cells. Wang et al [164] identified CDP/Cux as the 
principle component of this complex which mediates the negative regulatory 
activity attributed to NF-µNR. The CDP/Cux is the human (CDP, [165]) and 
mouse (Cux [166]) homologue of the Drosophila homeodomain protein, cut, 
which determines the cell fate of several embryonic tissue origins [167, 168]. 
Other members of this family include the rat CDP-2 protein [169] and the 
canine Cut-like homeobox factor (Clox) [170]. 
The CDP family constitutes a unique group of conserved homeoproteins 
among higher eukaryotes. The CDP/Cux proteins contain a single 
homeodomain and three cut repeats (Fig.7), and each of them is a highly 
conserved DNA binding domain. CDP/Cux also contains a coiled-coil leucine 
zipper (LZ) close to the N terminus and two active repression domains at the C 





















Fig. 7. Schematic diagram of CDP/Cux 
Coiled-coil leucine zipper (LZ) domain and homeodoman (HD) are indicated. Three cut 
repeats, CR1, CR2 and CR3, are highlighted in red boxes. Two active repression domains 





The homeodomain in CDP/Cux is a specific DNA-binding motif of 61 
amino acids, which is encoded by a 183 bp DNA element, the homeobox. The 
homeodomain is important for substrate specificity. Proteins containing this 
domain function as transcriptional regulators of differentiation and development. 
The homeodomain folds into three alpha helices, and two of them form a helix-
turn-helix (HTH) conformation, which is a common characteristic of 
transcriptional factors that can bind to the major groove of DNA [173, 174]. The 
third helix is the recognition helix that is responsible for DNA-binding specificity. 
A TAAT motif is conserved in almost all homeodomain binding sites, and 
homeodomain proteins prefer to bind these sites. The T at the 5’ terminal is 
crucial for the interaction, because its mutation totally abolished homeodomain 
binding [175]. However, other binding sites with divergent DNA sequences 
have also been reported [175]. 
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The cut repeats are approximately 70 amino acids in length and they 
have subtle differences in DNA binding specificity [165, 176, 177]. The cut 
repeats 2 and 3 bind to A+T rich DNA sequences, but they discriminate among 
similar sequences. Each of the three cut repeats have been shown to be 
independent DNA-binding motifs [176, 178] and prefer to bind to either CCAAT 
or ATCNAT sequences. As monomers, the individual cut repeats and the 
homeodomain do not interact with DNA very efficiently, but various 
combinations of cut repeats and homeodomains showed distinct DNA-binding 
specificity and kinetics [176, 178]. Compared with other transcriptional 
regulators, CDP/Cux appears to have greater flexibility in interacting with a 
wider spectrum of DNA sequences. In addition, the DNA-binding activity of 
CDP/Cux was reported to be regulated during cell cycle progression through its 
interaction with the core promoter of the cyclin kinase inhibitor, p21 [179]. 
CDP/Cux is evolutionarily conserved, and it is expressed from 
Drosophila to humans in various tissues. Originally CDP/Cux was identified as 
a transcriptional repressor, and a number of genes have been reported to be 
negatively regulated by CDP/Cux [180-186]. The CDP/Cux protein was 
reported to displace and compete for the binding of a CCAAT box-binding 
factor to negatively regulate the histone H2B gene in sea urchin [187]. CDP 
binding sites were found in the genes encoding human γ-globin [188, 189] and 
rat neural cell adhesion molecule (NCAM) [166]. CDP negatively regulates the 
human cytochrome gene, gp91-phox [190]. The repression mechanism of 
CDP/Cux may have a more general basis, because not all CDP/Cux binding 
sequence contain the CCAAT boxes [190].  
Liu et al. [147] demonstrated that CDP/Cux and SATB1 binding to a 
negatively regulatory element within the long terminal repeat of the mouse 
mammary tumor virus (MMTV) inhibits viral replication. Chattopadhyay and 
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coworkers [191] reported that both SATB1 and CDP/Cux bind to a MAR located 
immediately upstream of the TCRβ chain enhancer. Similar to what we 
observed with the L2a element [109], the two factors bind to distinct yet partially 
overlapping sites [191]. They found that inclusion of this MAR region decreased 
reporter expression in transfected thymoma cell lines, and mice bearing a 
knock out of this MAR have no TCRβ chain transcription in developing T cells. 
Their results suggested that this TCR-associated MAR element may be the 
target of both positive and negative regulation and that CDP/Cux acts as the 
negative regulator. 
CDP/Cux has been shown to repress gene expression by competing for 
binding site occupancy [184]. Generally, CDP/Cux competes with 
transcriptional activators for overlapping DNA binding sites to act as a 
repressor [165, 187, 190]. Furthermore, the C-terminal domain (CTD) of 
CDP/Cux is enriched in alanine and proline residues, which is a common 
property shared by many transcriptional repression domains. The cut and 
homeodomains of CDP/Cux were reported to interact with HDAC1 [182], and 
the direct recruitment of HDAC1 by CDP/Cux can mediate active repression of 
genes. The repression function of CDP/Cux has been reported to be regulated 
by post-translational modifications such as phosphorylation, acetylation, and 
proteolytic processing [179, 192-195]. 
In addition to acting as a repressor, CDP/Cux has been reported to 
activate transcription. The N-terminally truncated p110 CDP isoform was shown 
to stimulate DNA polymerase α promoter activity [196]. Cotransfection of CDP 
with the ITF2 factor induced tyrosine hydroxylase reporter gene activity [169]. 
Through interactions with different binding partners, CDP/Cux may have 
opposite functions on different promoters [197, 198]. 
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To study the in vivo function of CDP/Cux, two different strains of 
CDP/Cux knockout mice have been generated. ΔC1 mutant mice express a 
truncated protein with a deletion of 246 amino acids including CR1, but have an 
intact C-terminus [199]. The ΔC1 protein retains DNA-binding activity and can 
translocate to the nucleus. The homozygous mice showed hair defects, and a 
high portion of pup loss was found in females. The other CDP/Cux knockout 
strain, ΔC, has a targeted deletion of the homeodomain [200]. The homozygous 
mice show neonatal lethality, but the heterozygous mice were healthy and 
fertile. CDP/Cux expression levels were significantly decreased in the thymus 
and mammary glands of heterozygous mice [201]. Some defects in T cells and 
B cells were observed, suggesting that CDP/Cux may play a role in lymphoid 
development.  
 
1.5 Rational for this study  
The CD8a gene encodes the CD8 coreceptor for the recognition of 
peptide/MHC class I complexes by developing T lymphocytes in the thymus 
and for mature peripheral CD8 T lymphocytes. CD8 T lymphocytes play an 
important role in fighting viral infection and destroying cancer cells. 
Hostert and coworkers [56] constructed both the E8I enhancer and a 4.3 
kb HindIII/HindIII fragment spanning DH cluster II into a transgenic reporter. 
Their results indicated that this combination not only directed reporter 
expression in CD8 cells, as expected of E8I, but also directed expression in DP 
thymocytes [56]. The DH cluster II alone was unable to direct reporter gene 
expression in previous studies [52]; yet it permits expression of a reporter gene 
in DP thymocytes in combination with the E8I enhancer. Furthermore, knockout 
of 3.4 kb spanning DH cluster II (CII-1,2), which contains L2a, caused 
variegated expression of the CD8a gene [59]. 
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The observation that the cell type specificity of the E8I enhancer is 
extended to DP thymocytes by a DH cluster II fragment containing the L2a 
element is consistent with previous results  [106, 109] that L2a and its binding 
proteins play a role in the regulation of CD8a. Based on these observations, we 
wanted to test whether the L2a element, which was reported to inhibit CD8α 
expression in transfection studies in culturo [106, 109], regulates E8I enhancer 
function and CD8a gene expression in vivo.  Further, we wanted to determine 
if the L2a MAR in cluster II and its interacting proteins, SATB1 and CDP/Cux, 
are responsible for imparting DP thymocyte function to the E8I enhancer in vivo, 
or whether other sequences in cluster II were responsible. 
It has been established that MARs are important for regulation of gene 
expression, but the mechanism underlying their function is not well understood. 
The effects of MARs and MAR-binding proteins on gene transcription may 
result from the association of a regulatory region of gene with the nuclear 
matrix — a situation that may favor transcription. By studying the involvement 
of the L2a MAR and its associated proteins, SATB1 and CDP/Cux, in CD8a 
gene regulation, we may be able to address the role of the nuclear matrix in the 
function of this element. 
In addition to our observation that SATB1 and CDP/Cux interact with the 
L2a MAR region upstream of the mouse CD8a gene [109], three other groups 
have reported the binding of these two proteins to regulatory MARs [147, 191, 
202]. In most instances, CDP/Cux appears to be a negative regulator, and 
some have suggested that SATB1 also has a negative effect on gene 
transcription [145, 147]. The binding of these two proteins to regulatory MARs 
is likely to be a general phenomenon, and the studies involving the L2a element 
may provide general significance in interpreting this. 
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Studying the function of the MARs and MAR-binding proteins may provide 
clues for understanding abnormal gene expression associated with cancer and 
inherited diseases. Since the L2a MAR and other MARs frequently contain 
binding sites for topoisomerase II, which is a target for many anti-cancer drugs, 
understanding how MARs and their associated proteins regulate gene 























2. MATERIALS AND METHODS 
 
2.1 Preparation of nuclear extracts 
Nuclear extracts were prepared as described by Dignam et al. [203]. All 
steps were performed at 4oC or on ice. 2x108 cells were harvested and washed 
in PBS. The cells were resuspended in 5 ml buffer A (10mM HEPES [pH7.9], 
1.5mM MgCl2, 10mM KCl, 0.5mM DTT, and Protease inhibitor cocktail [Roche]) 
and incubated for 10 min. The cells were pelleted at 1,000g for 10 min and 
resuspended in 2ml of buffer A. A homogenizer with B pestle was used to lyses 
the cells (10 strokes), and the nuclei were pelleted at 1,000g for 10 min. The 
nuclei were washed with 2 ml of buffer A once and resuspended in 0.5-1.0 ml of 
buffer C (20mM HEPES [pH7.9], 25% glycerol, 0.42M NaCl, 1.5mM MgCl2, 
0.2mM EDTA, 0.5mM DTT, and Protease inhibitor cocktail), and homogenized 
with A pestle (20 strokes). Then the sample was magnetically stirred for 30 
minutes, pelleted at 15,000g for 30 min. The supernatant was recovered and 
dialyzed against buffer D (20mM HEPES [pH 7.9], 20% glycerol, 0.1M KCl, 
0.2mM EDTA, 0.5mM DTT, and Protease inhibitor cocktail) for 3 hours. After 
dialysis, nuclear extracts were centrifuged at 15,000g for 20 minutes, and 
supernatant was quick frozen in liquid nitrogen, and stored at -80oC. Protein 
concentration was determined by Bradford assay.  
 
2.2 Electrophoretic mobility shift assays (EMSAs)  
Nuclear extracts (2-5μg) were mixed with poly-(dI-dC)(2μg) in binding 
buffer (20mM HEPES [pH 7.9], 20% glycerol, 0.1M KCl, 0.2mM EDTA, 10mM 
DTT, and Protease inhibitor cocktail). Binding reactions were done in 25μl total 
volume at room temperature for 5 minutes. After 20 min incubation with end-
labeled probe (0.2ng), samples were electrophoresed at 120V for about 3 hours 
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through a 4% polyacrylamide gel (29:1) in 1xTBE buffer (90mM Tris-HCl [pH 
8.0], 90mM boric acid, and 2mM EDTA). Gels were dried for 1 hour and 
autoradiographed for 4 hours using a phosphoimage screen or overnight using 
films with an intensifying screen at -80oC. 
For competition assays, unlabeled competitor DNA fragments were 
added to the reaction before the addition of radiolabeled probes. For antibody 
inhibition assays, 2μl of appropriate dilutions of antibody were added to the 
reaction before the addition of radiolabeled probes. 
 
2.3 Preparation of probes for EMSA 
      All the probes were end-labeled with [α-32P]dATPs using exo-Klenow 
enzyme. L2a 200(L+S) probe and its mutant probes were cloned into 
pBluescript vector and excised out by appropriate restriction enzymes for end-
labeling. EMSA probes for the DH cluster II fragment and E8III fragment were 
created by PCR. BamHI or EcoRI restriction sites were added to the 5’ end of 
primers, and PCR amplified fragment were digested with both enzymes and 















Table 1. Primers used to make EMSA probes of E8III fragment.  
 
Probe name Primer Name Sequence (5'-3') 
P2 E3Bm3661F TTA GGA TCC TAG GAC TCC CAA AGC 
 E3BmR CAC ACC TTT AAT CCC AGT GC 
P3 E3Bm3661F TTA GGA TCC TAG GAC TCC CAA AGC 
 E3Er3844R TCA GAA TTC AAG GTT CTC CAA CG 
P4 E3Er3821F AAT GAA TTC TAG CCG TTG GAG AAC 
 E3BmR CAC ACC TTT AAT CCC AGT GC 
P5 E3Er3047F TGA GAA TTC AGC AGC CAT CTT ACT CTC 
 E3Bm3269R TCT GGA TCC TGG GAT TAA AGG CAT GC 
P6 E3Er3257F TGT GGA TTC TTT AAT CCC AGC ACT CG 
 E3Bm3464R TAT GGA TCC TAG CTT GTC TGA GGT C 
P7 E3Er3448F AGT GAA TTC AGA CAA GCT AGG AGT G 
 E3Bm3682R TAT GGA TCC TGG CTT TGG GAG TCC TAG 
P10 E3Er2840F TAA GAA TTC CCA CAC CAC CAT GTA C 
 E3Bm3071R ACT GGA TCC TGA GAG AGT AAG ATG GCT G 
P11 E3Er2685F TCA GAA TTC TAG TGA GAG ACA GC 
 E3Bm2867R ATT GGA TCC AAG AAG AGT ACA TGG TG 
P12 E3ScF ACC ATC CTA ACA GAG CTC TC 
 E3Bm2700R TTA GGA TCC GCT GTC TCT CAC TAG 
P13 E3Er2257F TCA GAA TTC TAC TCA CTG AGA CAT C 
 E3Bm2489R ACT GGA TCC TGA GAG CTC TGT TAG 
P14 E3Er2018F TCA GAA TTC TGT CTT AGA GCA TCC TC 
 E3Bm2280R ACT GGA TCC AGT AGG ATG TCT CAG 
P15 E3Er1682F TCA GAA TTC TAC ACA GTC AGG AGA TC 










Table 2. Primers used to make EMSA probes of DH cluster II. 
 
Probe name Primer Name Sequence (5'-3') 
L1 L2aEr4903F CTC GAA TTC ATC TCC GCA AAC AGC AAG 
 L2aBm5126R TTA GGA TCC ACT GAC AGC AGA CAA C 
L2 L2aEr5105F GTC GAA TTC CAG GTT GTC TGC TGT CAG 
 L2aBm5340R TAT GGA TCC TGA CTG TCC TGG ACC TCA C 
L3 L2aEr5505F GTC GAA TTC ATT GCC AGC ATG ATG 
 L2aBm5720R ATA GGA TCC ATC TGT TGG TGG AAG C 
L4 L2aEr5689F GTC GAA TTC CTT CTC AAA CGC TTC CAC 
 L2aBm5933R TCT GGA TCC ATG GCT TGC CTG AAA CTC 
L5 L2aEr5919F GTC GAA TTC AGG CAA GCC ATG GCT AC 
 L2aBm6156R TAT GGA TCC TGA AGC AGG CAG CAG AG 
L6 L2aHd6133F AGT AAG CTT CTG CTC TGC TGC CTG CTT C 
 L2aBm6368R AGT GGA TCC ATG CAG TGA GCT ATA GC 
L7 L2aHd6317F AGT AAG CTT AGC TGC AAG ACT TGA AG 
 L2aBm6582R AGT GGA TCC TGG TCA CTG CTT CTC CTA C 
L8 L2aHd6560F AGT AAG CTT CCT GTA GGA GAA GCA GTG 
 L2aBm6810R AGT GGA TCC ATA TGG TGT GCA TGT GTG 
L9 L2aHd6798F AGT AAG CTT GCA CAC CAT ATG CAC AC 
 L2aBm7024R AGT GGA TCC TAT CTC ACT CAT GCC TC 
L10 L2aHd7003F AGT AAG CTT ATG TGA GGC ATG AGT G 
 L2aBm7260R AGT GGA TCC ATC AAG GTT GTG GTA TG 
L11 L2aHd7240F AGT AAG CTT CAT ACC ACA ACC TTG ATG 
 L2aBm7489R AGT GGA TCC TCG AAC TCA GAA ATC 
L12 L2aHd7475F AGT AAG CTT CTG AGT TCG AGG CCA G 
 L2aBm7700R AGT GGA TCC ATG GTA ATA GTT GAC TG 
L13 L2aHd7665F AGT AAG CTT ACA TCT AAG AGA TAC AG 
 L2aBm7922R AGT GGA TCC TGT CTC AGC ATA TAA AG 
L14 L2aHd7906F AGT AAG CTT TAT ATG CTG AGA CAG 
 L2aBm8152R AGT GGA TCC TAC TAT GGC TTC CAA AG 
L15 L2aHd8135F AGT AAG CTT GGA AGC CAT AGT AGG TAC 




2.4 DNase I footprinting 
      The DNase I footprinting of isolated bands was performed as described 
by Landolf et al. [204] and Banan et al. [109]. Before the footprinting, a series of 
titrations of DNase I was set up with DNA sample to optimize digestion 
conditions. Ten EMSA reactions were set up with appropriate probes and 
nuclear extracts. After 15 min incubation, DNase I (Ambion) was added to the 
reactions at optimized concentration, and samples were incubated at room 
temperature for 5 minutes. Samples were loaded on a 4% polyacrylamide gel 
(29:1) and electrophoresed at 120V for about 3 hours. The retarded bands and 
free probes were excised from the EMSA gel after wet exposure of two hours. 
The samples were eluted in 0.2M NaCl-TE by crush and soak method [146], 
phenol:chloroform extracted and ethanol precipitated with 100μg/ml yeast tRNA. 
The dried DNA samples were resuspended in loading dye (1:2 0.1M 
NaOH:formamide (v/v), 0.1% xylene cyanol, 0.1% bromophenol blue) according 
to the radioactive counts. Samples with equal counts were electrophoresed 
through 8% sequencing gel. The markers were produced by PCR using DNA 
sequencing kit (Promega). 
 
2.5 Nuclear matrix binding assays 
Preparation of nuclear matrix was carried out as described by Reyes et 
al. [205]. Nuclear matrix was washed three times in 1 ml of wash buffer (10mM 
Tris-HCl [pH7.4], 50mM NaCl, 1mM KCl, 0.25M sucrose, 0.25mg/ml BSA, and 
Protease inhibitor cocktail), pelleted at 10,000 rpm, 1 minute at 4oC, and 
resuspended in 100μl of assay buffer (10mM Tris-HCl [pH7.4], 50mM NaCl, 
2mM EDTA, 0.25M sucrose, 0.25mg/ml BSA, 150μg/ml salmon sperm DNA, 
and Protease inhibitor cocktail). After incubation for 30 minutes at room 
temperature on an orbital shaker, 20,000 cpm of probe was added and reaction 
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was incubated for 90 minutes at room temperature with shaking. The sample 
was washed two times with final wash buffer (assay buffer less the protease 
inhibitor) and pelleted at 10,000 rpm for 10 minutes at 4oC. The pellet was 
resuspended in 50μl of TE buffer containing 0.5% SDS and 0.4mg/ml of 
proteinase K and incubated at 37oC overnight. 100μg/ml yeast tRNA was 
added to the sample and the mixture was phenol:chloroform extracted and 
ethanol precipitated. The DNA pellet was dissolved in DNA loading dye and 
separated on 4% polyacrylamide gels.  
 
2.6 Affinity chromatography 
Self-ligated PCR-amplified S+P3 probe was coupled to CNBr-activated 
Sepharose 4B beads (Amersham Pharmacia) to make the DNA affinity column. 
Nuclear extract prepared from BW5147 cells was diluted and passed through 
the uncoupled column first to trap non-specific protein binding, and then twice 
through the S+P3 column. The proteins that bind to S+P3 column were eluted 
with buffer of higher salt concentration. 
 
2.7 Cell lines 
The T cell lines VL3.B4 (from Dr. I. Weissman, Stanford University) and 
BW5147 were grown in DMEM media supplemented with 10% fetal bovine 
serum (FBS). 1200M T cell line (from Dr. Ellen Richie, M.D. Anderson Cancer 
Research Center) was cultured in RPMI media supplemented with 10% FBS. 
293T cells were cultured in DMEM media with 10%FBS. 
 
2.8 Transient transfection of cultured cells 
      293T cell transfections were carried out using Fugene 6 (Roche) 
following the product instruction. T cell lines were transfected by electroporation. 
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Briefly, 5x106 cells were washed and resuspended in 500μl PBS or culture 
media without FBS. Cells were mixed with 10μg of plasmid DNA and incubated 
at 4oC for 10 minutes. Electroporation was carried out with a Gene Pulser (Bio-
Rad), which was set at 950μF and 300V (for BW5147 or VL3 cells) or 220V (for 
1200M) cells. Cells were incubated on ice for 10 minutes after the 
electroporation, and 10-15 ml of media were added.  
 
2.9 Dual luciferase assays 
      L2a luciferase (Firefly) constructs were co-transfected with Renilla 
luciferase vectors into desired cell lines. 36-48 hours after transfection, cells 
were washed with PBS and resuspended in Passive Lysis Buffer (Dual-
Luciferase Reporter Assay System, Promega). The cell lysates were applied to 
dual-luciferase assay following product instruction. The Firefly intensities were 
normalized by Renilla intensities to obtain the relative activities. 
 
2.10 Production of transgenic mice 
      The L2a transgene construct was cut out of the vector using NotI, and an 
18 kb DNA fragment was purified for pronuclear microinjection. The C57BL/6 
zygotes were chosen to make transgenic mice to obtain an inbred background 
and save time from backcrossing.  After the microinjection of transgene 
construct, the zygotes that survived injection were cultured overnight and those 
that developed to 2-cell embryos were transferred into the oviducts of 0.5-dpc 
pseudopregnant female mice. Southern blot was used identify positive founders 
that developed from injected zygotes. Founders were bred to C57BL/6 to obtain 




2.11 Generation of L2a Knock-in mice 
The knock-in constructs (30μg) were linearized by NotI and transfected 
into 129SvEV embryonic stem cells using electroporation. Transfected ES cells 
were cultured on irradiated SNL76/7 cells, and G418 (Genticin, GIBCO) was 
added (200μg/ml) after one day. Ganciclovir was added (2μM) after an 
additional two days, and individual ES colonies were isolated approximately 
nine days after transfection. Half of each colony was frozen, and the remainder 
was used to prepare DNA for identification of recombinants.  Southern 
hybridization was used to screen for recombined positive clones using probe 1 
or 2 for left arm or right arm respectively.  
Correctly targeted ES cell clones were injected into day 3.5 C57BL/6J 
blastocysts and transferred into CD1 pseudopregnant females. Male chimeric 
mice were backcrossed to C57BL/6 females, and agouti progeny were 
screened for germline transmission of targeted gene by Southern blot of tail 
DNA. Mice carrying targeted gene were crossed with EIIA ubiquitous Cre mice 
to delete the neo gene. After the removal of the neo cassette, PCR was used to 
determine the neo-deleted allele. 
 
2.12 Preparation of genomic DNA from mouse tails 
Mouse tails were digested in 300μl of tail buffer (50mM Tris [pH8.0], 
100mM EDTA, 1% SDS, and 0.15mg/ml Proteinase K) at 55oC overnight. Tails 
samples were extracted sequentially with 300μl of phenol, phenol-chloroform 
(1:1), and chloroform, and the DNA was precipitated with 100μl of 30% PEG 
and 1.5M NaCl solution. DNA was pelleted (14,000rpm, 15 min), washed once 
with 70% ethanol, dried, and resuspended in 100μl of TE (10mM Tris-HCl, 
[pH8.0], 1mM EDTA).  
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2.13 Southern blot analysis 
The purified genomic DNA (25μg) was digested with restriction enzyme 
to completion. A 0.7% agarose gel was used to separate digested DNA by 
electrophoresis. The DNA was transferred to a nylon membrane (MSI), and the 
blot was hybridized overnight with random-primer labeled probes in Ultrahyb 
solution (Ambion). After hybridization, blot was washed twice with solution 
containing 2xSSC, 0.1% SDS at 55oC for 5 min, then washed twice with 
0.1xSSC, 0.1% SDS solution at 55oC for 15 minutes. Blots were air dried briefly 
and exposed using a phosphoimaging cassette. The [32P] labeled probes were 
generated by random primer synthesis using a decaprime DNA labeling kit 
(Ambion) 
. 
2.14 Isolation of cells from mouse thymus, lymph nodes and spleen 
     Thymus, lymph nodes and spleen were removed from euthanized mice 
and placed into 60mm dishes containing HBSS (Sigma) buffer. Tissues were 
passed through a 70 micron nylon cell strainer (BD Biosciences) to prepare 
single cell suspension. To remove red blood cells, isolated cells were incubated 
in RBC lysis buffer (0.5M NH4Cl, 0.15M Tris-HCl [pH7.65]) for 5 minutes at 
room temperature. Cells were washed with HBSS and ready for desired 
treatment and analysis. 
 
2.15 Isolation of IELs 
      The small intestine was removed from euthanized mice and washed with 
RPMI medium. The small intestine was turned inside-out over a glass tubing 
and incubated in 30ml of RPMI for 45 minutes at 37oC with low speed rotation 
to release the IELs. The RPMI medium containing released IELs was passed 
through a 70 micron cell strainer to filter out debris. Cells were centrifuged 
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(1,000rpm, room temperature) and resuspended in appropriate volume of RPMI 
medium. Cells were then purified with Ficoll-Pague Plus (Amersham) 
centrifugation (2,000rpm, 30min, room temperature), and washed with HBSS 
buffer.    
 
2.16 FACS staining 
      Isolated cells were washed with HBSS (Sigma) buffer twice at 1,000rpm 
4oC, and resuspended in Hanks buffer (HBSS with 2% FBS and 0.1% sodium 
azide) on ice. Cells were counted and 1x106 cells were used for subsequent 
staining. After incubation on ice with Fc-block (provided by Dr. Ellen Richie, 
M.D. Anderson Cancer Research Center) for 15 minutes, cells were stained 
with the desired antibodies for 45 minutes. Following two washes with 1ml 
Hanks buffer, 1ml HBSS once, cells were fixed using 1% paraformaldehyde 
and analyzed immediately. Cells requiring secondary antibody staining were 
incubated on ice with the appropriate reagent for 30 minutes after the wash 
steps of first staining. Cells were then washed and analyzed on a BD 
FACScalibur using CellQuest Pro software.  
 
2.17 Cell sorting 
Cells of interest were sorted and separated by a Magnetic Cell Sorting 
and Separation (MACS) System (Miltenyi Biotec GmbH). Briefly, cells were 
labeled by desired antibodies with magnetically labeled MicroBeads. After 
magnetic labeling, cells were passed through a separation column which was 
placed in a strong permanent magnet. The magnetically labeled cells were 
retained in the column, while the unlabeled cells passed through. The retained 
fraction was eluted and used immediately for culture and subsequent studies. 
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2.18 Pronase treatment 
      Pronase treatment was carried out as described by Suzuki et al. [206]. 
Magnetically sorted CD8 positive splenocytes were washed in PBS and 
resuspended in PBS containing 0.01% pronase (Sigma) at a concentration of 
2x106/ml. Cells were incubated for 15 minutes at 37oC, washed with PBS, and 
treated with pronase solution for another 15 minutes at 37oC. Pronase activity 
was quenched by an equal volume of FBS, and cells were washed and 
transferred to 12-well plates. Treated cells were incubated for 18 hours at 37oC 
or 4oC. Viable cells were harvested and analyzed by FACS. 
 
2.19 In vitro T cell activation 
      Isolated splenocytes were washed and resuspended in RPMI culture 
media. Cells were distributed to 24-well plates at a concentration of 2.5x106/ml 
and 2ml/well. Anti-CD3ε antibody (BD Biosciences) was added to the cells to a 
final concentration of 1μg/ml. Cells were sampled at day2 or day4 and applied 















3.1 Studies on in vitro interactions between L2a element and its binding 
proteins 
The L2a element has been identified as a MAR and interacts with two 
MAR-binding proteins, SATB1 and CDP/Cux [109]. Since they are both 
transcriptional regulators, the association of SATB1 and CDP/Cux with L2a is 
thought to be involved in its regulatory function of CD8 gene expression. Both 
proteins have distinct but partially overlapped binding sites in the L2a sequence, 
and a “switch displacement” model has been proposed to explain the 
interaction among L2a, SATB1, and CDP/Cux [109]. Various mutants of the 
L2a element were constructed to study the mechanism in more detail. 
 
3.1.1 Distance between L and S regions affects the binding of CDP/Cux to 
the L2a element 
Previous results of DNase I and missing nucleotide footprinting 
experiments suggested that CDP/Cux binds primarily to the S region of L2a 
element, although it can also interact with the L region [109]. Furthermore, a 
mutant containing a deletion of the S region totally abolished the binding of 
CDP/Cux to L2a [109]. It was proposed that CDP/Cux binding requires both the 
L and S regions. This unique binding pattern may be the key in understanding 
the basis for the displacement of CDP/Cux by SATB1 at the L2a element. To 
further test this, mutants with an elongated INTER-LS region were constructed 
and evaluated in DNA-protein interaction assays. 
To increase the length of INTER-LS region, one or more small DNA 
inserts were introduced between the L and S regions. An AflII restriction site 
was introduced immediately after the L region using GeneEditor in vitro Site 
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Directed Mutagenesis System (Promega). This mutation was made proximal to 
the L region to avoid interfering with the 12-mer palindromic sequence next to 
the S site. Two complimentary GC-rich oligos flanked by two AflII ends were 
annealed to make a 22-bp GC insert. The GC insert, introduced into the AflII 
site, was termed GC-1 (for one GC insert). Mutants GC-2 and GC-4 were made 
by inserting 2 and 4 GC inserts at the same site, respectively. Fig. 8A shows 
the mutated L2a constructs with GC inserts. 
EMSA assays were performed with BW5147 nuclear extract and either 
radiolabeled wild type L2a 200(L+S) probe or mutant (GC-1, GC-2, or GC-4) 
probes (Fig. 8B). BW5147 is a CD4 CD8 double-negative thymoma cell line 
that expresses CDP/Cux but not SATB1 protein (data not shown). EMSA 
results showed that, with increased number of GC inserts, the binding of 
CDP/Cux to the probes became weaker. This suggested that both L and S 
regions may be needed for CDP/Cux binding. When the distance between the L 
and S regions became longer, perhaps CDP/Cux could span both sites at the 
same time. Association with only one binding site may result in weak binding. 
Furthermore, even the longest insert (GC-4) could not totally abolish binding, 
suggesting that intact, individual S and L sites interact with CDP/Cux but cannot 













Fig. 8. L2a mutants with GC inserts show altered binding of CDP/Cux. 
A. Wild type L2a element 200 (L+S) and mutants with GC inserts. GC-1, one GC insert; 
GC-2, two GC inserts; GC-4, four GC inserts. B. EMSA performed with BW5147 nuclear 







The L2a element has been shown to be a nuclear matrix associated 
region (MAR) [109]. MARs are mostly AT rich DNA sequences. Therefore, to 
eliminate the possibility that the GC content of the inserts employed above may 
affect the binding activity of CDP/Cux, L2a mutants with random sequence 
inserts were created using a similar method. Mutants RD-1, RD-2, and RD-3 
have one, two, and three 22-bp random inserts respectively (Fig. 9A). EMSAs 
were performed with BW5147 nuclear extract and radiolabeled 200(L+S) probe, 
or mutant probes with random inserts (Fig. 9B). A decrease in binding was 
observed when the number of RD inserts increased. This result is consistent 
with that obtained from EMSA performed with GC inserts. Both GC inserts and 
random inserts seem to have the same effects on the binding of CDP/Cux to 
the L2a element. Thus, the change in length, but not content, of the DNA 
sequence is the main reason underlying these observations. 
To confirm the previous EMSA results, competition EMSAs were 
performed using unlabeled GC mutant probes. As shown in Fig. 10, unlabeled 
probes differed in their abilities to compete with the wild type probe for 
CDP/Cux binding. These results indicate that probes with longer GC inserts 
have weaker competition than the wild type probe; ie, the bigger the insert, the 
weaker it competes relatively to wild type probe. Competition EMSA was also 
performed with unlabeled mutant competitor probes with RD inserts, and the 
results (Fig. 11) were consistent with that obtained with the GC mutants. These 
competition assays support the previous EMSA results, suggesting that the 
distance between L and S regions can affect the binding activity of CDP/Cux to 








Fig. 9. L2a mutants with random (RD) sequence composition inserts show altered 
binding of CDP/Cux. 
A. Wild type L2a element 200 (L+S) and mutants with RD inserts. RD-1, one RD insert; 
RD-2, two RD inserts; RD-3, three RD inserts. B. EMSA performed with BW5147 nuclear 












Fig. 10. Competition EMSA indicates weaker binding of CDP/Cux to mutant probes 
with GC inserts. 
Competition EMSA performed with BW5147 nuclear extract, radiolabeled 200(L+S) probe, 
and unlabeled mutated GC-1, GC-2, GC-4 competitors. 10-200 molar excess of 



















Fig. 11. Competition EMSA indicates weaker binding of CDP/Cux to mutant probes 
with RD inserts. 
Competition EMSA performed with BW5147 nuclear extract, radiolabeled 200(L+S) probe, 
and unlabeled mutated RD-1, RD-2, RD-3 competitors. 10-200 molar excess of 








DNase I footprinting assays were employed to study how the binding of 
CDP/Cux to the L2a element decreased after the distance between L and S 
regions was changed. Fig. 12 shows the footprinting results performed with 
BW5147 nuclear extract and either 200(L+S) or mutant (GC-1 or GC-2) probes. 
Protection was observed of both L and S regions, and when the numbers of 
inserts in the INTER-LS region were increased, protection of both L and S 
regions decreased. This result is consistent with the EMSA results performed 
with BW5147 nuclear extract. The GC-4 probe was not used for footprinting 
because its EMSA complex with CDP/Cux was too weak to be isolated from the 
gel. 
 
3.1.2 SATB1 shows a different binding pattern to mutant probes 
To further characterize the interactions among CDP/Cux, SATB1 and the 
L2a element, nuclear extract from the VL3 cell line was utilized in EMSAs. VL3 
is a CD8 positive T cell tumor cell line, which expresses both CDP/Cux and 
SATB1 proteins. Fig.13 shows an EMSA performed with BW5147 or VL3 
nuclear extract, and radiolabeled 200(L+S), 300(L+S) probe or mutated GC 
probes. The wild type 300(L+S) was obtained from a different restriction 
digestion (PvuII) and was used as a control since it is the same size as GC-4. 
When using the VL3 nuclear extract, the SATB1 complex was super-shifted as 
the size of the probe increased. It appeared that the separate complexes for 
SATB1 and CDP/Cux merged into one complex when GC-4 was used as a 
probe. The 300(L+S) and GC-4 probes produced distinctly different CDP/Cux 
and SATB1 binding patterns. Thus, the size of the probes is not the reason why 
the binding pattern is changed.  Instead, the results from VL3 nuclear extract 
suggest that the inserts in the INTER-LS region affect the binding activities of 






Fig. 12. DNase I footprinting indicates decreased binding of CDP/Cux to L2a. 
DNase I footprinting performed with BW5147 nuclear extract, 200(L+S), GC-1, and GC-2 
mutated probes. Retarded bands of probe-protein complex and free probes were excised 
from EMSA (DNase I treated) gels for footprinting analysis. Protected regions are labeled 













Fig. 13. SATB1 shows a different binding pattern to GC mutant probes. 
EMSA performed with BW5147 nuclear extract, VL3 nuclear extract, radiolabeled 200(L+S), 












An EMSA was also performed with mutant RD probes, and similar 
binding patterns were observed (Fig.14). The SATB1 complex shifted to a 
higher mass, and it merged into the CDP/Cux complex when the RD-3 probe 
was used. When the PAL-1 probe (which contains the palindromic 12-mer of 
L2a) was used with the VL3 nuclear extract, only a single complex was 
observed. Comparing RD-1 and PAL-1, which are the same size and have 
similar structures, it seems likely that the presence of a single palindromic 
insert was responsible for altering the binding patterns of CDP/Cux and SATB1 
to the L2a element. This indicates that the palindromic 12-mer in the INTER-LS 
region is critical for the binding of CDP/Cux and SATB1 to L2a. 
Next, we used anti-CDP/Cux and anti-SATB1 antibodies in EMSAs to 
confirm the identity of the complexes observed in the previous experiments. In 
Figs. 15 and 16, the EMSAs were performed with the antibodies added to the 
nuclear extract before the addition of probes. When SATB1 protein was 
immunodepleted in this fashion, CDP/Cux produced the expected binding 
pattern (ie, similar to the EMSA performed with BW5147 extract). However, 
following depletion of CDP/Cux, SATB1 still showed a super-shifted binding 
pattern with increased sizes of the probes.  
One explanation for this result is that the binding of SATB1 to mutant 
probes causes a conformation change in the DNA. It is known that SATB1 
binding sites normally show a propensity to became stably base-unpaired [146]. 
It is possible that the binding of SATB1 might cause changes in the base-
unpairing of the mutant L2a probes, and unpaired DNA may be responsible for 
the retardation of these SATB1-DNA complexes. Another explanation is that 
there might be another protein involved in the interaction of the L2a element 






Fig. 14. SATB1 shows a different binding pattern to RD mutant probes. 
A. Wild type L2a 200(L+S) and mutant PAL-1 with one PAL insert. B. EMSA performed 
with BW5147 nuclear extract, VL3 nuclear extract, radiolabeled 200(L+S), and mutated RD 
















Fig. 15. CDP/Cux binding to L2a is unaltered in the absence of SATB1. 
EMSA performed with VL3 nuclear extract, radiolabeled 200(L+S) and mutated GC probes. 
Anti-SATB1 antibody was added to nuclear extract before incubation with the probes. The 




















Fig. 16. SATB1-L2a DNA complex is super-shifted in the absence of CDP/Cux. 
EMSA performed with VL3 nuclear extract, radiolabeled 200(L+S) and mutated GC probes. 
Anti-CDP antibody was added to nuclear extract before the probes. The arrows indicate 









To further investigate the binding properties of SATB1 and CDP/Cux, 
DNase I footprinting was performed with VL3 nuclear extract as described 
previously. As shown in Fig.17, protection of both L and S regions were 
observed in the retarded CDP/Cux complex. As the numbers of inserts in the 
INTER-LS region were increased, protection of both L and S regions decreased; 
but the trend of the decrease was not as obvious as that of the footprinting 
performed with BW5147 nuclear extract. 
The footprinting results from the retarded SATB1 complexes 
demonstrated that there is protection of both the L and the S regions and that 
the L region seems to be the primary site. When the number of inserts in the 
INTER-LS region is increased, the protection of the S region had little change, 
whereas the L region remained strongly protected. This suggested that SATB1 
binds to the L site constitutively. Interestingly, the DNase I hypersensitivity of 
the INTER-LS region upon SATB1 binding changed dramatically. For the wild 
type 200(L+S) L2a probe, a DNase I hypersensitivity site, consistent with what 
had been previously described [109],  appeared near the palindromic 12-mer. 
Using the GC-1 and GC-2 probes, significant DNase I hypersensitivity was 
displayed near the palindromic 12-mer which spread across the entire INTER-
LS region. When the GC-4 probe (containing 4 inserts) was used, no 
hypersensitivity was observed in the INTER-LS region. This suggested that 
SATB1 binding did not altered the conformation of GC-4 DNA.  These results 
raise the possibility that SATB1 cannot alter DNA conformation over a long 
distance (GC-4, 88bp insert), but a shorter distance (GC-2, 22bp; GC-2, 44bp) 








Fig. 17. DNase I footprinting indicates a conformational change(s) is induced within 
the L2a element upon SATB1 binding. 
DNase I Footprinting performed with VL3 nuclear extract, 200(L+S), GC-1, GC-2, and GC-
4 mutated probes. Retarded bands of probe-protein complex and free probes were excised 
from EMSA (DNase I treated) gels for footprinting analysis. Protected regions are labeled 
as L and S. 
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3.1.3 L2a mutants have altered nuclear matrix binding  
It has been shown that the sequences required for binding of both 
CDP/Cux and SATB1 contribute to the matrix-binding properties of the L2a 
element [109]. Thus it was important to know if changing the distance between 
the L and S regions would alter the matrix-binding properties of L2a. A standard 
in vitro nuclear matrix binding assay [205] was used to exam such effects. 
Fig. 18 shows the matrix-binding activities of L2a mutants with nuclear 
matrix prepared from EL-4 T cells. Compared to the positive control (BrMAR) 
previously shown [207] to be a strong MAR, the L2a element and its mutants 
weakly bound the nuclear matrix. When the distance between L and S regions 
was increased, L2a mutant binding was decreased, and the interaction of GC-4 
with the nuclear matrix was significantly weaker than that of wild type L2a. This 
result suggested that the nuclear matrix binding properties of the L2a element 
are altered by increasing the distance between the L and S regions. 
 
3.1.4 Multiple unidentified proteins bind to the palidromic 12-mer.  
Our previous results demonstrated that a single palindromic insert 
disrupted the normal binding pattern of CDP/Cux or SATB1 to the L2a element 
(Fig. 14), suggesting that the palindromic 12-mer may play a role in these 
interactions. When BW5147 nuclear extract was used to perform EMSA with 
L2a, a couple of unidentified complexes migrated below the CDP/Cux complex 
(Fig. 8-11, 13, 14). Since palindromes are frequently sites for protein 















Fig.18. L2a mutants have altered nuclear matrix binding activity. 
Linearized, radiolabeled plasmids containing different L2a mutants (GC-1, GC-1, and GC-4) 
were employed in an in vitro nuclear matrix binding assay. Linearized, radiolabeled empty 
vector (negative control) and BrMAR (an established MAR, positive control) were 










A mutant probe, Nco11, with two point mutations disrupting the 
palindromic 12-mer, was constructed and employed in EMSA (Fig. 19A). The 
retarded bands A and B of putative unidentified proteins disappeared were 
eliminated (Fig. 19B), suggesting that the 12-mer may be their binding site. 
Interestingly, the mutant probe favored the binding of SATB1 to the L2a 
element when VL3 nuclear extract was used, further indicating that the 12-mer 
may crucial to these interactions.  
Three additional constructs were made by inserting the palindromic 
sequence (PAL) into the middle of the 12-mer (Fig. 20A). Mutants PL-1, PL-2, 
and PL-3 have one, two, and three PAL inserts, respectively. As shown in Fig. 
20B, the intensities of bands A and B increased when probes with additional 
12-mers were used. These results suggest that probes with additional 12-mers 
bind stronger.  
Competition experiments were carried out using annealed palindromic 
oligos (PAL) and random sequence oligos (RAD) as competitors in EMSAs 
performed with BW5147 nuclear extract, 200(L+S), and PL-3 probes (Fig. 21). 
The palindromic oligos were found to compete with 200(L+S) and PL-3 probes. 
They specifically reduced, and even eliminated, the formation of complexes A 
and B, whereas the random oligos had no effect. These results suggest that the 
palindromic 12-mer may be the binding site of unidentified proteins. 
 
3.1.5 Identification of the 12-mer binding proteins     
The two retarded L2a palindromic binding complexes (A and B) were 
estimated from the EMSAs to run at 50-80 KDa. They were present in EMSAs 
performed with the CD8 and SATB1-negative BW5147 nuclear extract. DNA-
affinity chromatography was used to purify the proteins that specifically interact 






Fig. 19. Mutations of a palindromic 12-mer within L2a abolish unidentified protein-
DNA complexes formed in BW5147 nuclear extract. 
A. Schematic of L2a showing 12-mer and two point mutations (red) within (Nco11 probe). 
B. Left, two independent EMSAs performed with BW5147 nuclear extract, 200(L+S), and 
Nco11 probes. Complexes A and B are indicated by arrows. Right, mutations in 









Fig. 20. Insertion of additional 12-mers into L2a probes lead to stronger bands A and 
B. 
A. Wild type L2a and mutant PL probes with PAL inserts. PL-1, one palindromic insert; PL-
2, two PAL inserts; PL-3, three PAL inserts. B. EMSA performed with BW5147 nuclear 












Fig. 21. Palindromic oligos specifically compete with 200(L+S) and PL-3 probes for 
formation of bands A and B. 
Competition EMSA performed with BW5147 nuclear extract, radiolabeled 200(L+S) probe 
(left), PL-3 (right) and unlabeled ligated palindromic or random oligo competitors.  
PAL oligo: 5-TTAACACCCTAGGGTGAGATC-3’;  








To determine the DNA ligand for the affinity purification, three 
truncations of mutant probe PL-3, which has three palindromic inserts and 
exhibited the strongest binding in EMSA, were constructed by PCR. Probe 
L+P3 consists of the L region and three PAL sequences; probe S+P3 consists 
of the S region and three PAL sequences; probe P3 has only the three PAL 
inserts (Fig. 22A). As shown in Fig. 22B, the P3 probe bound weakly to proteins 
found in complexes A and B. Probe S+P3 produced stronger A and B bands 
than P3, whereas probe L+P3 failed to form either complex. This result 
suggests that both the S region and palindromic sequence are required for 
formation of bands A and B, and probe S+P3 is the best DNA sequence for 
affinity purification because it produces strong A+B bands and abolishes the 
binding of CDP/Cux. 
Ligated PCR-amplified S+P3 probe was coupled to CNBr-activated 
Sepharose 4B beads to make the DNA affinity column. Nuclear extract 
prepared from BW5147 cells was diluted and passed through the uncoupled 
column first to trap non-specific protein binding, and then twice through the 
S+P3 column. The proteins that bound to the S+P3 column were eluted with 
buffer at higher salt concentration. Eluted samples were applied to EMSA to 
check the efficiency of purification (Fig. 23A). These experiments indicated that 
CDP/Cux was completely depleted and the purified fraction retained binding 
ability to the 12-mer. Coomassie stained SDS PAGE revealed two abundant  
bands (Fig. 23B), and both of them were cut out of gel and sent to Core-facility 











Fig. 22. Determination of Probe S+P3 as the optimal DNA sequences for DNA-affinity 
purification of palindrome binding proteins. 
A. Mutant probes P3, S+P3, and L+P3 were created by PCR based on PL-3 probe. B. 
EMSA performed with BW5147 nuclear extract, 200(L+S) and mutant probes. Both S 















Fig. 23. Identification of two palindromic binding proteins by affinity purification. 
A. EMSA performed with purified 12-mer binding proteins, 200(L+S), and S+P3 probes. 
CDP/Cux was completely depleted and the purified fraction retained binding ability to S+P3. 
B. Coomassie stained SDS PAGE revealed two intensified bands, which were excised 











Based on the mouse genome database, MS revealed two candidates 
with high scores. One of them is the protein pigpen, which is a nuclear protein 
modulating endothelial cell differentiation [208]. Pigpen exhibits a complex 
structure, including a transcriptional activation (TA) domain, a zinc finger-like 
hairpin loop motif, a consensus tyrosine phosphorylation site, and two 
consensus RNA binding motifs [208]. The other protein identified by MS is an 
unnamed putative protein (gi/26334035). A search for conserved domains 
suggested it has a zinc finger structure and an actin depolymerisation factor 
(ADF)-like domain. 
Another candidate for the 12-mer binding protein was discovered after 
the analysis of the L2a sequence using a transcription binding factor data base 
(www.genomatix.de). The rat Olf-1/EBF associated zinc finger protein, ROAZ, 
binds to an inverted perfect or imperfect repeats of GCACCC separated by 2 bp 
[209]; this is almost identical to the 12-mer in the L2a element. Roaz is a C2H2 
zinc finger protein that plays a role in the regulation of olfactory neuronal 
differentiation [209]. This protein contains both a protein interaction and a DNA 
binding domain along with 29 C2H2 zinc fingers. This protein family also 
includes OAZ (Olf-1/EBF associated zinc finger, human) [210] and Ebfaz/Evi3 
(early B-cell factor associated zinc finger protein/ecotropic viral integration site 
3, mouse) [211]. Ebfaz/Evi3 has been shown to be essential for normal mouse 
B cell development and a frequently targeted locus for murine retroviral-
mediated leukemogenesis [211].   
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To determine if the OAZ family proteins interact with L2a element and 
the palindromic 12-mer, OAZ and Ebfaz cDNA constructs were obtained from 
the labs that identified them. Proteins were synthesized using an in vitro 
translation kit (Promega), and products were employed in EMSA using L2a 
probes. Unfortunately, in vitro translation failed to produce the detectable 
amounts of OAZ or Ebfaz proteins, probably, because of the complexity their 
structures (29 zinc-fingers). Further analyses are required to determine the 
identity of any of the putative 12-mer binding proteins. 
 
3.1.6 Cell transfection assays implicate the L2a element as a silencer 
To gather direct evidence for consequential CD8 transactivation via the 
L2a element, a series of luciferase vectors based on pGL3-basic (Promega) 
were constructed for use in transfection studies (Fig. 24A). Initial efforts to 
employ them in transient co-transfections of T cell lines, including BW5147 cells, 
VL3 cells and 1200M cells, gave low activities and inconsistent results (data not 
shown). Other efforts to introduce SATB1 into SATB1-null cells or to knock 
down SATB1 expression by siRNA were not successful (data not shown). Cell 
lines other than the above T cell lines were also employed in transfection 
assays using these L2a constructs. The embryonic kidney epithelial cell line, 
293T, yielded consistent but unexpected results. As shown in Fig. 24B, the 
construct L2aD-Luc, which lacks the L2a element, increased luciferase activity 
~2-fold as compared with the L2a-containing constructs, indicating a possible 









Fig. 24. Transfections of 293T cells suggest a negative regulatory role for L2a on the 
E8I enhancer.  
A. L2a luciferase vector series constructed for the transfection studies. Components of the 
constructs are highlighted in different colors. B. 293T cells were transfected with L2a 
luciferase constructs and Renilla luciferase vector. Cell lysates were measured for dual 












Fig. 25. Transfections of 1200M cells indicate a negative regulatory function of L2a 
on E8III enhancer. 
A. L2a-WE luciferase vector series was created based on WE310, 324 and 322 vectors. 
Components of the constructs are highlighted in different color. B. 1200M T cells were 
transfected with L2a-WE luciferase constructs and Renilla luciferase vector. Cell lysates 






Feik and coworkers [64] identified a 285 bp core enhancer within the 
E8III enhancer using luciferase assays. This was one of the few successful 
results obtained from transfection studies on CD8 cis-acting elements. We 
decided to test L2a in the context of the E8III enhancer using as starting 
materials the “WE” constructs discussed in that report [64] and kindly provided 
by Dr. Wilfried Ellmeier. A 220 bp L2a fragment was cloned upstream of the 
E8III fragment of each of the WE plasmids, and structures of all L2a-WE 
constructs are shown in Fig.25A. 1200M T cells were transfected with L2a-WE 
constructs, and results are shown in Fig. 25B. L2a-WE322, which contains the 
L2a element and the 285 bp E8III core, gave a ~2-fold decrease in relative 
activity compared to other constructs bearing E8III sequences. The activity of 
L2a-WE324 was not affected, perhaps because the distance between L2a and 
the core enhancer is longer than that of L2a-WE322. These results suggest a 
possible negative role for L2a when in cis with E8III.  
 
3.1.7 EMSAs revealed two more SATB1binding regions in DH cluster II 
      A knockout study suggested that targeted deletion of a 3.4kb genomic 
region (DH cluster CII-1 and CII-2) containing the L2a element leads to 
variegated CD8 expression in thymocytes [59], even though DH cluster II was 
inactive as a transgene [52]. Thus, it seemed possible that multiple cis-acting 
elements (besides L2a) are present in this region. Seventeen probes (each 
~250 bp) spanning the entire 4.3 kb HindIII/HindIII cluster II region were 
constructed by PCR (Fig. 26). EMSAs performed with VL3 cell nuclear extract 
identified two additional SATB1 and CDP/Cux binding sites present in DH 
cluster II (Fig. 26). L10 and L12 are close to each other and are separated by 
L11, a weak binding site for both proteins. Multiple CDP/Cux binding sites were 
observed in the EMSA above, and assays preformed with BW5147 nuclear 
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extract yielded similar results (Fig. 27). Antibody super-shifts confirmed that the 
complexes produced by L10 and L12 contained SATB1 and CDP/Cux (Fig. 28). 
     The newly identified STAB1 binding sites are proximal to the second DH 
site in cluster II (CII-2), and the L2a element is near the DH CII-1 site. Another 
SATB1 binding site, identified in the E8III enhancer (see below) is located close 
to the third DH site of cluster IV, CIV-3. This overlap between SATB1 binding 
sites and DNase I hypersensitive sites supports the previous notion [159] that 
SATB1 is important for remodeling chromatin. The presence of SATB1 binding 
sites may provide useful clues to identify new DNA cis-acting elements. 
 
3.1.8 An additional SATB1 binding site within the E8III enhancer 
      Recent studies suggest that the CD8 enhancer E8III may function in the 
proposed coreceptor reversal process during positive selection of thymocytes 
[65]. Unpublished results from our laboratory (H. Nie, personal communication) 
suggested that SATB1 is required for coreceptor reversal in CD8SP cell 
development. This was based on the observation that DP thymocytes isolated 
from SATB1-null mice and then stimulated in culture with PMA+I initially 
terminate CD8 transcription to become CD4+8– thymocytes, but never re-initiate 
CD8 transcription. Since both the SATB1 protein and E8III enhancer appear to 
be important for the co-receptor reversal process, additional efforts were made 



















Fig. 26. Identification of two additional SATB1 binding regions within DH cluster II. 
EMSA performed with VL3 cell nuclear extract and radiolabeled DH cluster II probes 




















Fig. 27. Multiple CDP/Cux binding sites are present within DH cluster II. 
EMSA performed with BW5147 cell nuclear extract and radiolabeled DH cluster II probes 
























Fig. 28. Antibody supershift/EMSAs confirmation of additional (non-L2a) binding 
sites for SATB1 and CDP/Cux within DH cluster II. 
Supershift/EMSAs were performed with VL3 cell nuclear extract, radiolabeled L10, L11, 
and L12 probes. Anti-SATB1 or anti-CDP antibodies and pre-immune serum were added 












EMSAs were used to determine potential SATB1-binding regions in the 
E8III enhancer. A 4 kb EcoRI/BamHI sub-region of E8III has been shown to be 
active in transgenic assays [57], and further studies using a 1.5 kb SacI/BamHI 
fragment demonstrated that E8III is involved in coreceptor reversal [65]. Ten 
probes of approximately 200 bp that span ~2.2 kb across the SacI/BamHI 
fragment were constructed (Fig. 29). Restriction sites for EcoRI and BamHI 
were appended to the 5’ ends of the PCR primers, and amplified probes were 
cut by both enzymes and purified for [32P] end labeling. 
Nuclear extracts of Jurkat T cells, which express both SATB1 and 
CDP/Cux proteins, were used in EMSAs to determine if SATB1 can interact 
with any of these E8III probes (Fig. 29). P12, which is located at the 5’ end of 
1.5 kb region, produced two retarded bands. Antibody super-shift/EMSAs 
confirmed that the lower and upper bands are SATB1 and CDP/Cux, 
respectively (Fig. 31A). Another weaker SATB1-associated region was found in 
probe P5. Binding of CDP/Cux to P5 was almost undetectable (Fig. 31B). The 
retarded band observed with probe P2 (which contains the 285 bp E8III core 
enhancer) was also confirmed as a CDP/Cux complex (Fig. 31C).  
The above experimented were repeated with nuclear extract prepared 
from VL3 T cells. Interestingly, P12 and P5 probes failed to form SATB1 
complexes (Fig. 30). However, the CDP/Cux bands remained intact with P12 as 
well as with P2 and P7. One possible reason responsible for these different 
binding patterns is that the interaction between E8III sites and SATB1 may be 
cell-type dependent. Jurkat cells are CD4+CD8–, and VL3 cells are CD4–CD8+. 
Perhaps SATB1 may be differentially post-translationally modified to function 
uniquely in specific cell types. If this is the case, SATB1 could interact with the 
E8III enhancer in CD4SP T cells to render it active (or inactive) to function at 
this stage. The enhancer might become inactive (or active) in CD8SP cells, 
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because modified SATB1 fails to bind to it. As a further extension to this 
hypothesis, SATB1 might assist the E8III enhancer in driving the coreceptor 
reversal process during the CD4+CD8low stage. Modification of SATB1 would 
result in lost activity once the transition to the CD8SP stage is initiated. 
CDP/Cux formed a complex with probe P2, a 285 bp AvaI/BamHI 
fragment, which was previously identified as the core region of the E8III 
enhancer in luciferase assays [64]. When we replaced the 285 bp core with the 
SATB1-binding P12 and P5 fragments identified above, no significant change in 
relative luciferase activities were observed (data not shown). Our transient 
transfection assays may not have been capable of identifying the function of 
SATB1, which has been implicated in regulating tissue-specific gene 
























Fig. 29. Additional SATB1 binding sites are present within the E8III enhancer. 
EMSA performed with Jurkat cell nuclear extract and radiolabeled E8III probes covering a 
2.2 kb region. The order of probes loaded in wells is not same as that shown in schematic 















Fig. 30. E8III probes that bind SATB1 in Jurkat nuclear extract do not form SATB1 
complexes in VL3 nuclear extract. 
EMSA performed with VL3 cell nuclear extract and radiolabeled E8III probes covering a 2.2 
kb region. The order of probes loaded in wells is not same as that shown in schematic map 
above. P12 and P5 probes do not form SATB1 complex in VL3 nuclear extract. The arrow 




















Fig. 31. Supershift EMSAs confirmed additional binding sites for SATB1 and 
CDP/Cux within the E8III enhancer. 
A and B. EMSAs performed with Jurkat cell nuclear extract, radiolabeled E8III P12 and P5 
probes. Anti-SATB1 or anti-CDP antibodies as well as pre-immune serum were added to 
the reaction before the addition of radiolabeled probes. The arrows indicate SATB1 or 
CDP/Cux complexes. C. EMSA performed with BW5147, VL3 nuclear extracts, and 
radiolabeled E8III P2 probe. Anti-CDP antibodies and pre-immune serum were added to 









3.2 Transgenic studies on the function of L2a element  
In previous stable transfection studies, inclusion of the L2a element (as a 
900 bp AccI/HpaI fragment) within their constructs significantly reduced the 
frequency of CD8α+ transfectants, suggesting that L2a may be a negative 
regulatory sequence on CD8 transcription [106]. Hostert and coworkers 
reported that a 4.3 kb HindIII/HindIII fragment containing DH cluster II, a 
fragment that is inactive in transgenic studies [52], allows the E8I enhancer to 
activate a reporter gene in DP thymocytes [56]. A transgenic approach was 
employed to further test if the L2a element, which is located within the first DH 
site of cluster II (CII-1), is responsible for modifying the specificity of the E8I 
enhancer in vivo. 
 
3.2.1 Generation of transgenic mice expressing a CD8 reporter with or 
without L2a. 
A hCD2 reporter gene was employed for the transgenic studies. It was 
derived from a mouse CD4 reporter gene construct produced by Sawada and 
coworkers [78] and contains the mouse CD4 exon I, a portion of intron I lacking 
the CD4 silencer, and the untranslated portion of exon II (a CD4 splicing 
module) fused to a human CD2 cDNA [212] with the SV40 polyadenylation site. 
Ellmeier et al. modified this reporter gene by replacing its CD4 promoter 
fragment with a polylinker, and a PCR-amplified mouse CD8a promoter [213] 
was inserted into the polylinker to make a construct called Tg-a [55].  
Fig. 32A shows the schematic map of the constructs used for our L2a 
transgenic study. The production of transgenic constructs was carried out under 
collaboration with Dr. Wilfried Ellmeier, University of Vienna. Briefly, a PCR-
amplified HindIII/ClaI CD8a promoter fragment was cloned into the pBluescript 
vector, and a 4.3 kb HindIII/HindIII DH cluster II fragment containing L2a 
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element was introduced upstream of the promoter. The 7.6 kb BamHI/BamHI 
fragment containing the E8I enhancer was subcloned upstream of 4.3 kb 
fragment, and a hCD2 reporter gene was inserted downstream of the promoter 
at the ClaI site. Transgene constructs were excised out of the vector by NotI 
and an 18 kb fragment was used for C57BL/6 pronuclear injections. Pronuclear 
injections were performed directly into C57BL/6 pronuclei. While much lower in 
efficiency, we employed C57BL/6 as recipients in order to eliminate strain 
effects and circumvent long backcross regiments. Southern hybridization was 
used to identify transgenic positive mice. The number of integrated copies was 
determined by comparing signal intensities of wild type and transgene-
containing bands (Fig. 32B). 
In addition to the wild type construct (L2aWT), a 4 kb DH cluster II 
fragment with deletion of the 210 bp L2a sequence was used to make the L2aD 
construct (Fig. 32A). A construct with a reversed orientation of the 4.3 kb L2a-
containing fragment (L2aR) was also constructed. 
 
3.2.2 CD8 reporter (hCD2) expression in both thymocytes and mature T 
cells is silenced in L2aWT transgenic mice  
      Fig. 32 shows the FACS analysis of thymocytes isolated from seven 
independent transgenic mice carrying the L2aWT transgene. Cells were stained 
with anti-CD4, anti-CD8a and anti-hCD2 antibodies, and then subjected to 
three-color FACS analysis. Expression of the hCD2 reporter gene on gated DP, 











Fig. 32. Transgenic constructs designed to test the effect of L2a on E8I function. 
A. Schematic of the transgenic constructs. Components of the constructs are highlighted in 
different colors and detailed in the text. The L2a element (red) resides in the first DH site of 
DH cluster II. L2aD has a deleted 200 (L+S) sequence in the HindIII/HindIII fragment and 
L2aR has an inverted one. B. Southern hybridization was used to identify positive 
transgenic mice, and the copy numbers were determined by comparing signal intensities of 






Surprisingly, six out of seven transgenic mice showed very low to 
undetectable levels of hCD2 expression in all three subsets of thymocytes. This 
contradicts results published previously [56]. These six transgenic strains 
lacked reporter expression in CD4SP or DP cells, but four of them showed 
significant hCD2 levels within a small portion (1-5%) of the CD8SP thymocytes. 
Because the E8I enhancer alone was shown to be sufficient for driving 
transgene expression in CD8SP cells [54, 55], this low frequency of cells 
capable of reporter expression level may suggest certain repressive effect on 
E8I from the L2a containing DH cluster II fragment.  
The small group of hCD2 positive CD8SP cells observed in four L2aWT 
mice had reporter levels (MFI: 42-91) similar to that of L2aWT1 (MFI: 69). This 
suggests that the repressive effect of L2a may be silencing in the mode of a 
binary (on/off) switch. That is, rare cells that by-pass L2a-mediated silencing 
would have normally regulated CD8 transcription, resulting in variegated 
expression of CD8 reporter (as reported in our transgenes by hCD2) within the 
CD8SP subset. The L2a containing DH cluster II fragment may play a role as a 
silencer for the reporter expression driven by E8I enhancer.   
Only one L2a-containing transgenic line, L2aWT1, expressed high levels 
of hCD2 in CD8SP (80.4%) and DP (80.3%) cells. This is the one exception 
from the L2aWT group of “escape” from the apparent repressive effects of L2a. 
We suspect that this results from a strong position (euchromatin) effect of 









Fig. 33. Silenced reporter expression in thymocytes of L2aWT transgenic mice. 
FACS analysis of thymocytes isolated from seven independent L2aWT transgenic mice. 
Cells were stained with anti-CD4, anti-CD8α and anti-hCD2 antibodies, and were applied 
to three-color FACS analysis. Expression of the hCD2 reporter gene on gated DP, CD4SP, 
and CD8SP thymocytes were analyzed in histograms. Percentages and MFIs of hCD2 




Fig. 34. Silenced reporter expression in lymph node T cells of L2aWT mice. 
FACS analysis of lymph node T cells isolated from seven independent L2aWT transgenic 
mice. Cells were stained with anti-CD4, anti-CD8α and anti-hCD2 antibodies, and were 
applied to three-color FACS analysis. Expression of the hCD2 reporter gene on gated CD4 
and CD8 lymphocytes were analyzed in histograms. Percentages and MFIs of hCD2 




Peripheral lymph node cells were also examined by three-color FACS 
analysis (Fig. 34). The CD8 positive cell subsets (except L2aWT1) showed 
similar hCD2 expression patterns as those observed in CD8SP thymocytes. 
Again, we observed a small population of hCD2 positive cells (2-9%) with 
significant MFI (61-107), consistent with the existence of a CD8 silencer that 
when circumvented provides variegated expression.  
Neither CD4SP thymocytes (except L2aWT1) nor peripheral CD4 T cells 
expressed hCD2 on their surface, confirming the CD8 subset specificity of the 
transgenic E8I-driven construct. Among all L2a transgenic mice (including 
L2aWT mice and L2aD mice to be discussed below), each independent line 
expressed consistent levels of hCD2, due (we suspect) to the pure C67BL/6 
background. No significant variation of reporter expression was observed in any 
transgenic line after 2-3 generations. 
 
3.2.3 CD8 reporter (hCD2) expression in both thymocytes and mature T 
cells is rescued by deletion of L2a in L2aD transgenic mice.  
Fig. 35 shows the FACS analysis of hCD2 expression on isolated 
thymocytes from the L2aD transgenic mice in which the L2a element has been 
deleted. Significant expression was observed in CD8SP and DP thymocytes in 
four out of five L2aD mice. This is consistent with observations by Hostert and 
coworker [56] showing that the DH cluster II fragment (lacking L2a) facilitates 
E8I enhancer-driven reporter expression in DP thymocytes. Combined with the 
results from L2aWT transgenic mice (Fig. 33), the data indicate that the L2a 







Fig. 35. DH cluster II without L2a restores reporter expression in DP thymocytes of 
L2aD transgenic mice. 
FACS analysis of thymocytes isolated from five independent L2aD transgenic mice. Cells 
were stained with anti-CD4, anti-CD8α and anti-hCD2 antibodies, and were applied to 
three-color FACS analysis. Expression of the hCD2 reporter gene on gated DP, CD4SP, 
and CD8SP thymocytes were analyzed in histograms. Percentages and MFIs of hCD2 
positive (>1.0%) subsets and numbers (n) of mice tested are shown. 
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Another potentially informative observation was that CD4SP thymocytes 
from these four L2aD transgenic mice expressed detectable levels of hCD2 on 
their surface (Fig. 35).  This suggests that this apparent of loss of E8I-
mediated subset specificity is lost if L2a silencing is lost. L2aD3 was the only 
strain that did not express a transgene on any thymocyte subset in this group. 
This may be the result of transgene integration into a constitutively silenced 
heterochromatic region. Analysis of mature T cells from lymph nodes showed 
similar robust CD8 reporter expression in the CD8 positive cells (Fig. 36). 
Since the L2a element was not required for driving hCD2 expression in 
DP thymocytes, other cis-acting DNA elements may be responsible for this 
function. Two additional, strongly binding SATB1 sites have been identified 
(Results section 3.1.7), and these may be good candidates for further study. 
Why our results differ from those obtained by Hostert and coworkers [56] 
may be revealed by a closer comparison of the transgenes employed (Fig. 
32C). Hostert et al. placed the E8I enhancer (CIII) and DH cluster II 
downstream of the hCD2 reporter. This is the opposite (3’ with regard to CD8 
transcription) side of the germline configuration and the configuration of our 
construct. Although some reports [54-57] suggest that the orientation of CD8 
enhancer(s) is not a factor affecting reporter expression, this may not be the 
case for L2a. In the single line (L2aR) that we created in which the orientation 
of L2a was reversed, hCD2 was strongly expressed in both CD8SP and DP 
thymocytes (data not shown). This suggests that the silencing function of the 








Fig. 36. DH cluster II without L2a allows reporter expression in CD8 positive T cell in 
L2aD transgenic mice. 
FACS analysis of lymph node T cells isolated from five independent L2aD transgenic mice. 
Cells were stained with anti-CD4, anti-CD8α and anti-hCD2 antibodies, and were applied 
to three-color FACS analysis. Expression of the hCD2 reporter gene on gated CD4 and 
CD8 lymphocytes were analyzed in histograms. Percentages and MFIs of hCD2 positive 




3.2.4 Variegated reporter gene expression in L2aWT transgenic mice is 
stable. 
Splenocytes from L2aWT5 and L2aD5 transgenic mice were labeled with 
anti-CD8α MicroBeads (MACS System), and CD8+ cells were positively 
separated as described in Materials and Methods. Purified CD8 cells were 
treated with pronase (Sigma) and placed in culture at 37oC or 4oC as controls 
for 18 hours. As shown in Fig. 37, hCD2 expression on both L2aWT5 and 
L2aD5 sorted cells was up-regulated efficiently 18 hours after the pronase 
treatment. This result indicates that the transgenes have retained their ability to 
re-express the reporter molecules. Importantly, it allows us to conclude that the 
small fraction of hCD2+ cells in the presence of L2a (in L2aWT5) is the product 
of variegated expression. Some of the hCD2 molecules expressed on the cell 
surface were retained after treatment, suggesting they were more resistant to 
pronase than were CD8 molecules. 
 
3.2.5 Expression of CD8 reporter transgenes by CD8αα+ IELs is similar to 
that of conventional CD8αβ+ T cells 
      It is known that the CD8αα homodimer is expressed in IELs within the 
small intestine and in a subset of dendritic cells (DCs) [90]. To determine if the 
hCD2 gene, which is driven by the E8I enhancer and CD8a promoter, is co-
expressed on the cells bearing the CD8αα homodimer, IELs were isolated from 
both L2aWT and L2aD transgenic mice and were tested for reporter expression. 
IELs were stained with either the combination of anti-CD8α, anti-CD8β and 
anti-hCD2 antibodies or the combination of anti-TCRγδ, anti-CD8β and anti-
hCD2 antibodies. Gated IEL subsets were analyzed for reporter expression (Fig. 
38). 









Fig. 37. Variegated expression of reporter gene in L2aWT mice is stable. 
The sorted CD8+ populations were treated with pronase and placed in culture at 37oC for 
18 hours or 4oC as controls. hCD2 and CD8 expression on both L2aWT5 and L2aD5 
sorted cells were upregulated efficiently 18 hour after the pronase treatment. Percentages 










As shown in Fig. 38, the hCD2 levels within both CD8αα+ and CD8αβ+ 
IELs isolated from the L2aWT3, 4 and 5 strains showed similar silencing as 
those isolated from lymph node T cells. Furthermore, variegated reporter 
expression was also observed in IELs of L2aWT mice. Fig. 39 shows the hCD2 
expression pattern observed in IELs isolated form L2aD mice which lack the 
L2a element in the transgene. Expression was observed on both CD8αα and 
CD8αβ subsets at levels comparable levels to that on lymph node CD8+ cells. 
This result is consistent with previously published results that E8I enhancer 
directs the reporter expression on IELs [57]. Observations from both groups of 
mice support the conclusion that the L2a element is a silencer that controls 
CD8 expression (both CD8αα and CD8αβ) in IELs as well as in thymocytes and 
mature T cells. 
      Comparing all the cell subsets tested for L2aWT and L2aD transgenic 
mice, the expression pattern (both percentage of positive cells and MFI) of the 
hCD2 reporter in IELs is similar to those of thymocytes and CD8+ T cells. This 
implies that CD8 expression in IELs may be regulated under a similar 
mechanism as in thymocytes. Our evidence weighs in favor of a common 
thymic lineage origin and against the long-time debate [214] regarding 













Fig. 38. Expression of hCD2 reporter gene on IELs is similar to those of CD8 positive 
T cells in L2aWT mice. 
IELs were isolated from four L2aWT transgenic mice, and were stained with either the 
combination of anti-CD8α, anti-CD8β and anti-hCD2 antibodies (left)or the combination of 
anti-TCRγδ, anti-CD8β and anti-hCD2 antibodies (right). Gated IEL subsets were analyzed 













Fig. 39. Expression of hCD2 reporter gene on IELs is similar to those of CD8 positive 
T cells in L2aD mice. 
IELs were isolated from four L2aD transgenic mice, and were stained with either the 
combination of anti-CD8α, anti-CD8β and anti-hCD2 antibodies or the combination of anti-
TCRγδ, anti-CD8β and anti-hCD2 antibodies. Gated IEL subsets were analyzed for hCD2 










3.2.6 CD8 transgene reporter expression differs between dendritic (DC) 
cells and CD8 positive T cells 
     In the mouse spleen, a subset of DCs expresses CD8αα homodimers. 
These CD8αα+ DCs were originally considered lymphoid progenitors [215], but 
more recent results indicate that they have developed from both myeloid and 
lymphoid progenitors [90]. To test whether the E8I enhancer and DH cluster II 
fragment-containing L2a can regulate hCD2 expression in the DCs, 
splenocytes were isolated from L2aWT8 and L2aD5 mice and were analyzed 
by FACS. Cells were stained with anti-CD11c, anti-CD8α and anti-hCD2 
antibodies, and the analysis of gated cells is shown in Fig. 40. 
      The CD11c+CD8α+ DCs from L2aWT8 and L2aD5 expressed detectable 
levels of the hCD2 reporter, but expression was much lower than that in 
CD11c–CD8+ T cells. The MFIs of CD8α on CD11c+CD8α+ DCs and CD11c–
CD8α+ splenocytes were similar (data not shown). Thus, the regulation of 
CD8αα expression in DCs may differ from that of T cells, or additional cis-acting 
elements may be needed for this regulatory process.     
  
3.2.7 CD8 transgenic reporter expression is modulated via TCR signaling  
Recent studies showed that CD8αα molecules are transiently induced in a 
selected subset of CD8αβ+ cells upon antigenic stimulation, and they promote 
the survival and differentiation of activated lymphocytes into memory CD8 T 
cells [102]. E8I enhancer knockout mice do not produce these cells, suggesting 
that the induction of CD8αα on activated CD8αβ+ splenocytes is controlled by 
the E8I enhancer [102].  Since the hCD2 reporter of our transgenic constructs 
is under the control of the E8I enhancer and the L2a DH cluster II fragment, we 















Fig. 40. CD8 reporter expression on dendritic cells differs from that on CD8 positive 
T cells in L2a transgenic mice 
Splenocytes isolated from L2aWT8 and L2aD5 mice were stained with anti-CD11c, anti-
CD8α and anti-hCD2 antibodies. Gated cells were analyzed as shown. Percentages and 










Splenocytes from both L2aWT and L2aD transgenic mice were cultured 
with or without purified anti-CD3ε antibody, and expression of the hCD2 
reporter was analyzed by FACS on day 4 (Fig. 41). All three L2aWT mice 
tested showed decreased reporter expression (reduced MFI) upon anti-CD3 
stimulation, but the hCD2 levels were not affected in splenocytes from L2aD 
mice. It appears that the TCR activation strengthened the silencing of hCD2 
expression by L2a, and deletion of L2a abolishes further silencing caused by 
simulation. These results suggest that the L2a element may function as a 
silencer in CD8αα-regulated memory T cell selection. 
 
3.2.8 Reduced levels of SATB1 or CDP/Cux proteins cause modest 
changes in CD8 transgene expression. 
      To examine the effects of SATB1 and CDP/Cux on the regulation of CD8 
expression in the presence and absence of L2a, we bred L2aWT and L2aD 
transgenic mice with previously established SATB1-reduced [158] and 
CDP/Cux knockout (ΔC) [201] mice (kindly provided by Dr. Jaquelin Dudley). 
 To cross the L2a transgene onto the SATB1-reduced background, 
L2aWT and L2aD mice were bred to homozygous SATB1 antisense (As/As) 
transgenic mice to obtain L2a/+, As/+ mice. One backcross with As/As mice 
produced L2a/+, As/As mice. Then these mice were bred to SATB1-reduced 
mice (As/As, SATB1 KO/+), such that 25% of the offspring were the desired 
L2a/+, As/As, SATB1 KO/+ genotype. 
The homozygote of ΔC mice is lethal, but the heterzygous mice show 
significantly reduced (less than 50%) CDP/Cux expression in the thymus and 
mammary glands [201]. To generate the CDP/Cux reduced L2a transgenic 
mice, L2aWT and L2aD mice were crossed to heterozygous ΔC mice. The 






Fig. 41. Expression of CD8 transgenic (hCD2) reporter is modulated by TCR 
signaling.  
Splenocytes from three L2aWT and two L2aD transgenic mice were cultured with or 
without purified anti-CD3ε antibody, and expression of the hCD2 reporter were analyzed by 










When the L2aWT2 mice were crossed onto a SATB1 knockdown 
background, the small fraction of both CD8SP thymocytes and CD8 T cells 
demonstrating variegated hCD2 expression was decreased (Fig. 42). This 
indicates that SATB1 is involved in re-starting silenced CD8 expression 
mediated by L2a. As shown in both Figs. 42 and 43, expression of the hCD2 
reporter (MFI) decreased modestly on all CD8-expressing subsets, especially in 
DP thymocytes under the reduced SATB1 background. Both L2aWT and L2aD 
transgenic mice showed decreased hCD2 levels, indicating that SATB1 is 
required for maintaining reporter expression. Since other cis-acing elements in 
the DH cluster II are responsible for driving CD8 reporter expression in DP 
thymocytes, these unknown elements may the targets of SATB1. 
Thus, SATB1 may play two roles in regulating CD8 expression. It 
functions to overcome L2a silencing at certain developmental stages to assist 
in re-expression of CD8, such as the transition from CD4+CD8low to CD8SP 
cells during the corecepter reversal process. Meanwhile, once CD8 expression 
is established, SATB1 may work with other cis-acting elements within DH 
cluster II to maintain the expression of CD8. 
The expression of hCD2 in CDP/Cux reduced mice also showed modest 
changes (Fig. 44). Increased reporter levels were observed in CD8 thymocytes 


















Fig. 42. Reduced levels of SATB1 protein results in modest changes in CD8 reporter 
expression in L2aWT mice 
L2aWT1 and L2aWT2 transgenic mice were crossed to SATB1 reduced mice. Expression 
of the hCD2 reporter on thymocytes and lymph node T cells was analyzed by FACS. 





















Fig. 43. Reduced levels of SATB1 protein causes modest changes in CD8 reporter 
expression in L2aD mice 
L2aD1 and L2aD2 transgenic mice were crossed onto SATB1-reduced mice to place the 
L2a transgene onto the reduced SATB1 background. Expression of the hCD2 reporter on 
thymocytes and lymph node T cells were analyzed by FACS. Percentages and MFIs of 















Fig. 44. Reduced levels of CDP/Cux protein cause modest changes in CD8 reporter 
expression in L2aWT and L2aD mice. 
L2aWT and L2aD transgenic mice were crossed onto CDP/Cux knockout (ΔC) mice to 
place the L2a transgene onto the reduced CDP/Cux background. Expression of the hCD2 
reporter on thymocytes and lymph node T cells was analyzed by FACS. Percentages and 
MFIs of hCD2 positive (>1.0%) subsets are shown. 
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3.3 Targeted deletion/knock-in studies on the function of the L2a element  
It has been reported that a targeted deletion of a 3.4kb genomic region 
(DH cluster CII-1 and CII-2) containing the L2a element led to abnormal 
thymocyte development characterized by a large population of thymocytes that 
never turn on CD8 gene expression and a decrease in the thymic and 
peripheral CD8SP T cell population [1]. Our transgenic studies reported above 
suggest that the L2a element may be a silencer of CD8 gene transcription. To 
further investigate the putative role of L2a in the natural chromosomal context 
in vivo, knock-in mice were produced with deletion or mutations in the L2a 
element. 
  
3.3.1 Generation of the L2a Knock-in mice 
The targeting construct was generated as shown in Fig. 45. Two 
genomic fragments were cloned into a pOSDupDel vector (Open Biosystems) 
containing the HSV-tk gene (not shown). The left homology arm of the 
construct is a 2.3kb SphI-BamHI fragment of the wild type locus. The longer 
right homology arm is a 7.8kb BamHI-NotI fragment. Between the two arms, 
there is a neomycin resistance gene driven by the thymidine kinase promoter 
flanked by two loxP sites. The L2a wild-type or L2a mutated region is located 
on the right arm of the targeting construct. 
The knock-in constructs were linearized by NotI and transfected into 
129SvEV embryonic stem cells using electroporation. Southern hybridization 
was used to screen the recombinant clones using probe 1 or 2 for left arm or 
right arm, respectively (Fig. 45A, B). High recombination efficiencies in ES cells 
(KI-WT 8.6%; KI-ΔL2a 23.8%; KI-M1 21.4%) were observed, indicating that L2a 
might be located in euchromatic, accessible chromatin associated with active 
transcription of genes. 
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Fig. 45. L2a knock-in strategy and analysis. 
A. Schematic of the targeting construct, the CD8 locus before and after homologous 
recombination, the targeted locus, and the genomic locus after Cre recombinase-mediated 
deletion of the neo gene. B. Southern blots of Bgl II (left) and Bcl I (right) digested DNA 
isolated from a wild-type ES cell clone (+/+) and from an ES cell clone after homologous 
recombination (+/KI); Left arm (Probe 1/ Bgl II) and right arm (Probe2/ Bcl I). C. PCR 
genotyping of the targeted locus after the deletion of the neo cassette. The neo cassette 




Selected positive ES clones were injected into day 3.5 C57BL/6J 
blastocysts and transferred into (B6/D2) F1 pseudopregnant females. Male 
chimeric mice were backcrossed to C57BL/6 females, and agouti progeny were 
screened for germline transmission of the targeted gene by Southern blot 
analysis of tail DNA (Fig. 45B). Since the presence of the neo cassette could 
influence the results [2], mice carrying the targeted allele were crossed with 
mice that expressed Cre under ubiquitous E2A transcriptional control to delete 
the neo gene. After the removal of the neo cassette, PCR was used to confirm 
the neo-deleted allele (Fig. 45C).  
To investigate the function of the L2a element, more subtle modifications 
were introduced within specific sequences associated with binding proteins. 
Wild type L2a knock-in mice (KI-WT) were created as a control and the 200 
(L+S) deletion of L2a was introduced to make the KI-ΔL2a knock-in mice. Two 
L2a mutants, M1 and M4, generated in previous study [3] (Fig. 46) were 
subcloned into the knock-in targeting construct to make KI-M1 and KI-M4 mice. 
The M1 mutant contains mutations that abolish the binding of SATB1, but leave 
the binding of CDP/Cux intact; The M4 mutant binds SATB1 strongly and 
interacts with CDP/Cux very weakly. KI-WT, KI-M1 and KI-ΔL2a mice have 




















Fig. 46 L2a mutants for loss of SATB1 (M1) and CDP/Cux (M4) employed in knock-in 
studies. 
Previously created mutants M1 and M4 were cloned into the knock-in targeting construct to 
make KI-M1 and KI-M4 mice. M1 abolishes the binding of SATB1, but leaves the binding of 











3.3.2 Expression of CD8 is not affected in thymocytes and peripheral T 
cell subsets in mice lacking the SATB1 binding site (KI-M1) within L2a. 
Lymph node cells and thymocytes were isolated from homozygous KI-
WT and KI-M1 mice, stained with antibodies against CD4 and CD8α, and then 
analyzed by FACS. As shown in Fig. 47, the introduction of the M1 mutation 
(loss of SATB1 binding to L2a) did not alter the CD8 expression in thymocytes 
or lymph node T cells from KI-M1 mice. At least five pairs of mice were tested 
and none of them showed any significant changes. 
Different developmental T cell surface markers were tested in CD4SP, 
CD8SP and DP thymocytes. KI-WT and KI-M1 mice showed similar expression 
of CD3, CD5, CD24, CD44 and CD69 molecules (Fig. 48). RT-PCR was also 
used to measure CD8α transcription levels in both mice, and no significant 
changes were observed (data not shown). These results indicate the M1 
mutation that abolishes SATB1 binding to L2a does not affect CD8 expression 
and T cell development. 
      In addition, comparisons between KI-WT mice and C57BL/6x129/Sv 
mice indicated no differences in CD4, CD8 expression as well as other surface 
makers. This means that the inclusion of recombined loxP sites in KI-WT mice 



















Fig. 47. CD8 expression is unaffected in thymocytes and lymph node T cells from KI-
M1 mice. 
Lymph node cells and thymocytes were isolated from homozygous KI-WT and KI-M1 mice 
and stained with antibodies against CD4 and CD8α molecules, and the cells were 














Fig. 48. Expression of T cell surface markers is unaffected in KI-M1 mice. 
The indicated developmental T cell surface markers were tested on CD4SP, CD8SP and 
DP thymocytes. KI-WT and KI-M1 mice showed similar expression levels of CD3, CD5, 










3.3.3 T cells carrying complete L2a deletion (KI-ΔL2a) show modest 
changes in CD8 and CD4 expression 
Three out of five KI-ΔL2a homozygous mice showed changes in both 
CD4 and CD8 expression in thymocytes and lymph node T cells, whereas the 
other two showed no difference. Fig.49 shows the results from one of the three 
homozygous KI-ΔL2a mice. Both CD4SP and CD8SP thymocyte subsets were 
increased by about 50% (9.9% to 16.9%, 2.5% to 4.0%). CD4 and CD8 T cells 
in lymph nodes both increased modestly (15-20%). The MFIs of CD4 and CD8 
were the similar in all populations (Fig. 49).  
These results suggest that the deletion of the L2a element leads to 
increased numbers of both CD4 and CD8 cells. The increased CD8 cell number 
may be the result of deletion of a potential CD8 enhancer, whereas the 
increased CD4 cell population may indicate more complicated, cell non-
autonomous effects in the absence of L2a element. Considering that two of the 
KI-ΔL2a mice showed no changes, the phenotypes of these mice may be 
affected by subtle differences or some type of variegation among individual 
mice and variations among mouse strains (C57BL/6 vs 129Sv). More 
backcrosses to C57BL/6 are needed to obtain a pure background for 
establishing a more consistent phenotype.  
Thymocytes from KI-ΔL2a mice were tested for T cell developmental 
markers CD3, CD5 and CD69 (Fig. 50). The expression levels of these surface 












Fig. 49. KI-ΔL2a mice show modest changes in CD8 and CD4 expression. 
Lymph node cells and thymocytes were isolated from homozygous KI-WT and KI-ΔL2a 
mice and stained with antibodies against CD4 and CD8α molecules. The cells were 
analyzed by FACS. Percentages of each cell population are shown. Three out of five KI-
ΔL2a homozygous mice showed changes in both CD4 and CD8 expression in thymocytes 











Fig. 50. Expression of T cell surface markers is unaffected in ΔL2a mice. 
The indicated developmental T cell surface markers were tested on CD4SP, CD8SP and 
DP thymocytes. KI-WT and ΔL2a mice showed similar expression levels of CD3, CD5, and 









3.3.4 CD8αα and CD8αβ expression is modestly increased in IELs of KI 
mice 
      L2a KI mice were tested for expression of CD8αα homodimers in their 
IELs. As shown in Fig. 51, modestly increased CD8αα expression (both 
percentage and MFI) was observed on both TCRαβ+ and TCRγδ+ IELs from KI-
M1 mice. CD8αβ levels on TCRαβ IELs increased as well. The KI-ΔL2a mice 
showed similar changes in all three IEL subsets tested (Fig. 52). Although the 
observed increase in CD8 expression was modest, both KI-M1 and KI-ΔL2a 
mice showed a consistent trend toward greater CD8 expression on their IELs. 
These changes suggest that both M1 and L2a deletion mutations affect the 
function of L2a as silencer.    
 
3.3.5 The L2a element collaborates with E8I to promote CD8αα expression 
in activated lymphocytes 
The CD8αα molecules induced upon antigenic stimulation promote the 
survival and differentiation of activated lymphocytes into memory CD8 T cells, 
and this process is controlled by the E8I enhancer [4]. The L2a element and DH 
cluster II region have been shown to collaborate with E8I in transgenic studies 
[5]. Thus, it would be informative to determine whether L2a is involved in the 













Fig. 51. CD8αα expression is modestly increased on IELs from KI-M1 mice. 
Expression of CD8αα homodimers on IELs was tested in KI-WT and KI-M1 mice. IELs 
were stained, gated, and analyzed as shown above. Percentages and MFIs of positive 















Fig. 52. CD8αα expression is modestly increased on IELs from KI-ΔL2a mice. 
Expression of CD8αα homodimers in IELs was tested on KI-WT and KI-ΔL2a mice. IELs 
were stained, gated, and analyzed as shown above. Percentages and MFIs of positive 
cells are shown. In both KI-M1 (Fig. 51) and KI-ΔL2a mice, CD8αα homodimers on 
TCRαβ+ or TCRγδ+ IELs and CD8αβ heterodimers on TCRαβ+ IELs showed a trend toward 






Splenocytes from KI-WT, KI-M1 and KI-ΔL2a homozygous mice were 
cultured and stimulated with anti-CD3ε antibody. CD8αα expression was 
analyzed by staining with thymic leukemia (TL) tetramers (kindly provided by Dr. 
Hilde Cheroutre, La Jolla Institute of Immunology) after 4 days of culture. As 
shown in Fig. 53, activated splenocytes from KI-ΔL2a mice showed increased 
CD8αα expression upon stimulation. This increase in CD8αα is consistent with 
the hypothesis that L2a is a silencer, and its deletion has relieved repression of 
TCR-mediated induction of CD8αα expression—an event critical to survival and 
memory cell differentiation. 
 
3.3.6 Decreased CD8αα expression in dendrite cells of KI-ΔL2a mice 
The expression of CD8αα homodimers in a subset of DCs was analyzed 
as shown in Figs. 54 and 55.  The relative frequency of CD11c+ DCs from KI-
M1 mice that expressed CD8αα (27.4%) was indistinguishable from that of KI-
WT mice (20.4% and 27.5%). However, the frequency of CD8αα expressing 
DCs from KI-ΔL2a mice decreased significantly (8.8%). These data strongly 
suggest that the L2a element may function differently in the development of 









Fig. 53. L2a collaborates with E8I for CD8αα expression in activated peripheral T 
cells. 
Splenocytes from KI-WT, KI-M1 and KI-ΔL2a homozygous mice were cultured and 
stimulated with anti-CD3ε antibody, and CD8αα expression was analyzed by staining with 
thymic leukemia (TL) tetramers on day 4. Percentages and MFIs of positive cells are 
shown within each profile box. Activated splenocytes from KI-ΔL2a mice showed increased 
















Fig. 54. Unaltered CD8αα expression on dendrite cells of KI-M1 mice. 
The expression of CD8αα homodimers in a subset of DCs was analyzed as shown in 
previous FACS figures.  Percentages and MFIs of positive cells are shown. CD11c+ DCs 
from KI-M1 mice expressed the same level of CD8αα (27.4%) as those [Fig 54] of KI-WT 














Fig. 55. Decreased CD8αα expression on dendrite cells of KI-ΔL2a mice. 
The expression of CD8αα homodimers in a subset of DCs was analyzed as shown above. 
Percentages and MFIs of positive cells are indicated (/) inside the profile boxes. CD8αα 











4.1 The L2a MAR, SATB1 and CDP/Cux and the Displacement Switch 
Model  
Nuclear matrix-associated regions (MARs) are short AT-rich DNA 
sequences that are widespread throughout the eukaryotic genome, and have 
great affinity for the nuclear matrix in vitro [6, 7]. MARs have been postulated to 
mediate chromatin loop formation important for compaction of genomic DNA, 
and also to organize chromatin into units of genomic function [8, 9]. A stable 
transfection approach was used to define an ~200 bp cis-acting element (L2a) 
4.5 kb upstream of CD8a that appeared to be the target of negative regulation 
in hybridomas produced by fusion of CD8+ cells with BW5147 [10]. Prompted 
by the AT-rich nature of L2a, it was tested and confirmed to be a MAR using 
the conventional in vitro matrix binding assay. 
Several MAR-binding proteins have been identified, and two of these, 
SATB1 and CDP/Cux were shown to specifically interact with L2a [3]. 
Footprinting analysis demonstrated that two protected regions (L and S) are the 
binding sites of CDP/Cux and SATB1 [3]. On the basis of earlier studies of the 
cell type distributions of SATB1 and CDP/Cux and their interaction with the L2a 
element [3, 10], it was proposed that SATB1 and CDP/Cux play positive and 
negative roles, respectively, in CD8a gene regulation [3]. They suggested that 
binding of SATB1 displaces the CDP/Cux repressor from the L2a element and 
favors CD8α expression, probably by altering chromatin structure and/or 
allowing the L2a element and nearby CD8a gene to associate with the nuclear 
matrix [3]. This proposed model describing the interaction of SATB1 and 
CDP/Cux with the L2a element was termed as the Displacement Switch Model 
(Fig. 5). 
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The CDP/Cux protein contains a homeodomain and three cut repeats, 
and each of them may have specific, unique DNA binding activities [11, 12]. 
The results of EMSAs performed here with elongated L2a probes indicated that 
both the L and S regions are important for CDP/Cux binding (Figs. 8-12). 
Binding of CDP/Cux to the GC-4 probe was decreased dramatically but was not 
completely lost. This suggests that individual binding of CDP/Cux to the L or S 
region is not strong enough to maintain the interaction. Thus, DNA motifs that 
contain two binding sites separated by an appropriate distance may be the 
preferred target of CDP/Cux. Two binding sites may provide more options for 
other regulatory factors, such as SATB1, to compete for associated regions. 
This may provide the basis for the Displacement Switch Model. 
The interaction between SATB1 and elongated L2a probes yielded a 
supershifted binding pattern (Figs.13-16). Footprinting experiments indicated 
that the binding of CDP/Cux to L2a probes did not change the DNA 
conformation, whereas the interaction between SATB1 and L2a probes caused 
a dramatic increase in the DNase I hypersensitivity (Fig. 17). This implicated 
SATB1 as a positive regulator.  
In addition to the L2a element-associated SATB1 site, SATB1 binding 
sites were identified within DH cluster II and within the CD8 enhancer E8III (Figs. 
26-28). Interestingly, all the SATB1 sites identified in this report overlap with 
previously established [13] DH sites, suggesting that SATB1 is important for the 
chromatin remodeling process. This, coupled with the previously observed 
defects in CD8 expression under conditions of SATB1 deficiency [14, 15], 
suggests that SATB1 binding sites may be good candidates for additional DNA 
cis-acting elements critical to CD8 regulation. 
CDP/Cux was also found to bind to multiple regions within DH cluster II 
and within the E8III enhancer (Figs. 26-31), but only a few of them showed 
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strong interaction. Most of the complexes are relatively weak, suggesting they 
are not very specific or that they are only partially qualified for CDP/Cux binding 
according to the criterion discussed above. As for SATB1, fewer binding sites 
were found, and surprisingly, each SATB1 binding site identified was also a 
strong binding site for CDP/Cux. It appears that these two proteins work 
together as partners, since their binding sites are always, at least partially, 
overlapped. Similar observations were made by other groups [16, 17]. Thus, 
the Displacement Switch Model might have a more general basis and could be 
used to predict the consequences of the interactions among SATB1, CDP/Cux 
and their binding sites.  
Unpublished experiments from Ingrid Rojas (personal communication) 
using protein competition assays with SATB1 and CDP/Cux demonstrated that 
SATB1 binds predominantly to the L2a element. When bound together to L2a, 
SATB1 and CDP/Cux proteins did not interfere with each other, nor did they 
coimmunoprecipitate in VL3 and Jurkat nuclear extracts. These observations 
provide further evidence in support of the Displacement Switch Model. 
 
4.2 New cis-acting elements involved in CD8 expression 
The palindromic 12-mer in the INTER-LS region of L2a may be another 
regulatory sequence involved in CD8 expression. Introduction of one PAL insert 
into the INTER-LS region completely altered the binding patterns of SATB1 and 
CDP/Cux (Fig. 14 and 20). Two point mutations within the 12-mer weakened 
CDP/Cux binding and abolished complexes (termed A and B) formed by 
unidentified proteins (Fig. 19). These observations indicated that the 
palindromic 12-mer may be involved in the interaction of L2a with SATB1 and 
CDP/Cux. To do this, additional 12-mer binding factors might be recruited to 
this region.  
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Two 12-mer binding proteins were identified by affinity purification. One 
of these, pigpen, modulates endothelial cell differentiation [18], while the other 
is an EST without known function.  Both have DNA binding domains, and 
further functional study is required to determine their role in the context of the 
palindromic 12-mer. In addition, the OAZ family of proteins was found to have a 
preferred DNA binding site that is almost identical to the 12-mer [19]. Since 
OAZ proteins contain multiple DNA and protein interaction domains and are 
involved in several important biological functions [20, 21], it will be interesting to 
test if they can bind to the 12-mer and regulate CD8 expression. 
Our transgenic studies indicated that the L2a element might be a 
silencer of CD8 expression. The DH cluster II fragment without L2a drove E8I to 
activate a CD8 reporter in DP thymocytes, suggesting that other cis-acting 
elements in this region may be responsible (Fig. 33-36). We identified two 
strong SATB1 binding sites proximal to the second DH site of cluster II (CII-2) 
(Fig. 26). These might be good candidates for cis-acting elements that 
collaborate with the E8I enhancer. The results here and those of others indicate 
that the DH cluster II may be a complicated region, comprised of the putative 
L2a silencer and other positive regulatory elements. 
Both the E8III enhancer [22] and the SATB1 protein (H. Nie, personal 
communication) have been shown to be involved in the corecepter reversal 
process during positive selection of thymocytes. We identified a strong SATB1 
binding site near the 5’ end of the E8III enhancer (contained within a 1.5 kb 
SacI/BamHI fragment) (Fig. 29), which might be the target of the SATB1-
mediated effect. Since the 285 bp core portion of the E8III enhancer resides at 
the 3’ end of that fragment [23], E8III may also be a combination of enhancer 
and other cis-acting DNA elements. 
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4.3 The L2a element as a CD8 silencer 
      Transgenic studies reported here indicated that the L2a element is a 
CD8 silencer. In mice containing the L2a wild type transgene (L2aWT), CD8 
reporter (hCD2) expression is silenced in both DP and CD8SP thymocytes (Fig. 
33 and 34), suggesting that the L2a silencing may occur at an early 
developmental stage, such as DN. A small portion (~5%) of CD8SP thymocytes 
and CD8 T cells escaped silencing, resulting in variegated reporter expression 
within these two populations. When the L2a element was deleted (L2aD mice), 
significant expression of the CD8 reporter was observed in all CD8 expressing 
cells, including DP thymocytes (Fig. 35 and 36). 
      CD8 reporter expression on the cell surfaces of CD8αβ and CD8αα 
positive IELs from both L2aWT and L2aD mice were indistinguishable from the 
patterns observed on mature CD8 T cells (Fig. 38 and 39). We also detected 
“escaped” variegated reporter expression in these populations. These results 
suggest that CD8 expression in IELs is control by L2a silencing and that 
thymocytes and IELs may share a similar CD8 regulatory mechanism.  
When the L2WT mice were crossed onto a SATB1-deficient background, 
the small fraction of “escaped” variegated-expressing CD8SP thymocytes and 
CD8 T cells was reduced (Fig. 42). This suggests that SATB1 is involved in re-
starting silenced CD8 expression mediated by L2a. That SATB1 might 
overcome L2a silencing to re-express CD8 at certain developmental stage is 
consistent with unpublished results from our laboratory (H. Nie, personal 
communication).  Her analysis of SATB1-null mice indicated that SATB1 is 
indispensable for re-initiation of CD8 transcription during the coreceptor 
reversal process (transition from CD4+CD8low to CD8SP cells) during positive 
selection.  
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All the results from transgenic studies suggest that the L2a element is a 
silencer involved in CD8 expression, which is consistent with the negative 
regulatory role of L2a reported in previous results [10] and cell transfection 
results using L2a construct (Fig. 24 and 25). The L2a silencer may play an 
important role in the CD8 expression which is controlled by multiple enhancers 
and redundant regulation.  
 
4.4 Knock-in studies on the L2a element  
      We performed knock-in studies to further investigate the function of L2a. 
The M1 mutant knock-in mice, which have altered binding sites in the L2a 
element that abolish SATB1 interaction, showed no significant change in T cell 
development or in CD8 expression in thymocyte or in peripheral T cell subsets 
(Fig. 47 and 48). Three out of five knock-in mice (KI-ΔL2a) in which the entire 
L2a element was deleted had modestly increased numbers of CD8 thymocyte 
and CD8 peripheral T cell populations (Fig. 49). This result is consistent with a 
potential silencer function for L2a. IELs form both knock-in mice showed a trend 
of modestly increased CD8α expression in CD8αβ and CD8αα cells (Fig. 51 
and 52), further indicating that loss of SATB1 binding to the L2a element 
contributes to silencing CD8 in IELs.  
     All the modestly increased CD8 expression observed in thymocytes, 
peripheral T cells, IELs and activated lymphocytes (Fig. 47-53) indicates the 
consequence of the deleted L2a silencer. Compared to the more dramatic 
silencing observed in transgenic analyses, it is possible that compensatory 
effects of other cis-acting elements present in the germline configuration but 
missing from the transgenic locus may result in less significant effects observed 
in L2a mutant knock-in studies. 
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4.5 Function of L2a in dendritic cells 
The murine DCs have been classified into two lineages, lymphoid DCs 
[24] and myeloid DCs [25]. Based on expression of CD4 and CD8αα 
homodimer, which were thought to be expressed mainly on T cells, DCs can be 
further divided into different subtypes [26]. CD8αα+ DCs, which lack the myeloid 
maker CD11b, were originally thought to develop from lymphoid-committed 
thymic T cell progenitors at low frequencies [27]. CD8αα– DCs, which are either 
CD4+ or CD4– and generally express CD11b, were thought to arise from 
myeloid progenitors [28]. However, Traver et al. demonstrated that both 
CD8αα+ and CD8αα– DCs are generated from common myeloid and lymphoid 
progenitors in both mouse thymus and spleen [29]. Their results suggest that 
CD8αα on DCs reflects the differentiation or maturation status of DCs but does 
not indicate a lymphoid origin [29]. 
In our knock-in studies, CD8αα expression on the CD11c+ DCs (CD11c 
is a common maker for all DCs) was significantly decreased in KI-ΔL2a mice 
(Fig. 55). Unlike the function of a silencer in T cells and IELs, L2a may play a 
different role in the regulation of CD8αα expression in DCs. Furthermore, in L2a 
transgenic mice, a subset of CD11c+CD8αα+ DCs was shown to express the 
reporter at a much lower level than CD8 T cells (Fig. 40), suggesting that the 
regulation of CD8α expression in DCs is different from that of T cells.  
Both knock-in and transgenic studies suggest a possible different 
regulatory mechanism of CD8 expression between DCs and T cells. This 
indicates that the CD8αα+ DCs may not be, at least partially, derived from 
lymphoid lineage. The L2a element, which has been shown to be a silencer in T 
cells of lymphoid lineage, may play a different role in CD8αα expression in DCs 
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